NZ738078B2 - Mct4 inhibitors for treating disease - Google Patents

Abstract

Disclosed herein are pyrazole derivatives useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases. Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Description

/037213 MCT4 INHIBITORS FOR NG DISEASE This application claims the benefit of priority of United States provisional application no. 62/174,685, filed June 12, 2015, the contents of which are orated by reference as if written herein in their entirety.

This invention was made with government support under grant no. R43 CA189391 awarded by the National Institutes of Health. The government has certain rights in the ion.

The present disclosure relates to new cyclic compounds and compositions, and their application as pharmaceuticals for the treatment of e. Methods of inhibition of MCT4 activity in a human or animal subject are also provided for the treatment of diseases such as proliferative and inflammatory diseases.

Lactic acid export from glycolytic cells is typically mediated by the monocarboxylate transporter MCT4. MCT4 exhibits weak affinity for lactate (Km = 28 mM) coupled with a high turnover rate, allowing rapid export of large amounts of lactic acid.

MCT4 expression is normally limited to highly glycolytic tissues such as white muscle fibers, lymphocytes, astrocytes, and Sertoli cells. Though MCT4 is absent from most normal tissues, MCT4 expression is highly upregulated, and correlates with poor survival, in many cancer indications, ing colorectal cancer, glioma, head and neck cancer, triple-negative breast cancer, prostate , KRAS mutant lung cancer, liver cancer, and kidney .

The correlation of MCT4 expression and poor cancer outcome appears to be of significant functional consequence in multiple cancer . Stable expression of MCT4 is highly tumorigenic in a respiration-impaired, Ras-transformed fibroblast xenograft model.

Conversely, MCT4 silencing slows or ablates tumor growth in xenograft models of breast cancer, colorectal cancer, and . MCT4 expression is required for inflammatory cytokine ILmediated angiogenesis in breast and colon cancer xenograft models. MCT4 has also been shown to play important roles in cancer cell migration, invasion, and various aspects of the Warburg effect (e. g., proliferation on glucose, extracellular acidification, and lactate secretion).

Glycolytic reprogramming, ing MCT4 upregulation, is also required for pro-inflammatory functions of innate immune cells such as macrophages and dendritic cells.

The silencing of MCT4 leads to decreased inflammatory ses in macrophages. These findings suggest that MCT4 may play an ant role in innate immune cell mediated inflammatory diseases.

MCT4 has also been demonstrated to be important in the glycolytic metabolism of toid arthritis (RA) synovial fibroblasts, which are highly proliferative and are one of the key s in the joint destructive process of RA. Silencing of MCT4 in RA synovial fibroblasts significantly reduces the severity of arthritis in a mouse collagen-induced arthritis model.

Inhibition of MCT4-mediated lactic acid export may be an effective strategy to impair the Warburg effect in diseases including cancer and inflammatory disease.

Unfortunately, no potent and selective MCT4 inhibitors have been described. Moderate to weak MCT4 inhibitors are known (e.g, phloretin and OL-CNOH-cinnamate); however, these compounds promiscuously inhibit a number of other transporters, including MCTl.

Thus, there is a need for potent and selective MCT4 tors for use in the treatment or prevention of proliferative and atory es.

Accordingly, disclosed herein are new compositions and methods for inhibiting MCT4 activity.

Provided is a compound of structural Formula I X W ‘2 (I) or a salt thereof, wherein: A1, A2, and A3 are ndently chosen from N and C, wherein at least one of A1, A2, and A3 is N, L is chosen from a bond and methylene, W is chosen from o o o )fi/OfigkOCHg woogkNHz WOXLOH E's/0&0” R5 R4 R5 R4 and 9 , 7 3 wo%N,SOZCH3 R5 R4 H X is chosen from alkenyl, lamino, alkyl, aminoalkenyl, aminoalkyl, and H, any of which may be optionally substituted with one to three Rl groups, each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, koxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, Y is chosen from alkenyl, lamino, alkyl, aminoalkenyl, aminoalkyl, aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, wherein when X is not H, X and Y er with the atoms to which they are ed may form an aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring, any of which may be optionally substituted with one to three R7 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, and R4 and R5 are ndently chosen from H and C1-C6alkyl, with R4 and R5 together comprising no more than 6 carbons; and Z is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, koxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl.

Provided is a composition comprising a compound of FormulaI and a pharmaceutically acceptable carrier, nt, or vehicle.

Provided is a method for inhibiting activity of the monocarboxylate transporter MCT4, or a mutant thereof, in a biological sample comprising the step of ting said biological sample with a compound as recited in claim 1.

Provided is a method for inhibiting activity of the monocarboxylate transporter MCT4, or a mutant thereof, activity in a t comprising the step of administering to the patient a nd as recited in claim 1. ed is a method for ng a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof, comprising the step of administering to said patient a compound as recited in claim 1.

Provided is a method of treating a MCT4-mediated disorder in a subject in need thereof, comprising the sequential or co-administration of a compound of Formula] or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

Provided is a compound of any of Formula I for use in human therapy.

Provided is a compound of any of Formula I for use in treating a MCT4-mediated disease.

Provided is a use of a compound of Formula I for the manufacture of a ment to treat a MCT4-mediated disease.

DETAILED DESCRIPTION iations and Definitions To facilitate understanding of the disclosure, a number of terms and abbreviations as used herein are defined below as follows: When introducing ts of the present disclosure or the preferred embodiment(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

The term “a compound as disclosed ,” when used in pharmaceutical method of treatment, l use, method of tion, and similar embodiments, refers to any compound disclosed in a genus or subgenus or specifically exemplified herein.

The term "and/or" when used in a list of two or more items, means that any one of the listed items can be employed by itself or in combination with any one or more of the listed items. For example, the expression "A and/or B" is intended to mean either or both of A and B, i.e. A alone, B alone or A and B in combination. The expression "A, B and/or C" is intended to mean A alone, B alone, C alone, A and B in combination, A and C in combination, B and C in ation or A, B, and C in combination.

When ranges of values are disclosed, and the notation “from n1 to n2” or “between n1 and n2” is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be al or continuous between and including the end . By way of e, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 uM molar),” which is intended to include 1 uM, 3 uM, and hing in between to any number of significant figures (e.g, 1.255 uM, 2.1 uM, 2.9999 uM, etc).

The term “about,” as used herein, is intended to qualify the numerical values that it modifies, denoting such a value as variable within a range close to the value. When no particular range, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.

As used herein, two embodiments are “mutually exclusive” when one is defined to be something which is different than the other. For example, an embodiment n Y is specified to be thienyl is mutually ive with an embodiment in which Y is specified to be phenyl. However, an embodiment wherein Y is specified to be thienyl is not mutually exclusive with an embodiment in which Z is ortho-substituted with an R3 group chosen from alkoxy, alkyl, alkylamino, halo, and kyl.

The term “acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a —C(O)CH3 group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a yl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.

The term “alkenyl,” as used , alone or in combination, refers to a straight- chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkenyl will comprise 2016/037213 from 2 to 6 carbon atoms, The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH=CH—), (—C: :C—)].

Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4- butadienyl and the like. Unless ise specified, the term “alkenyl” may include ylene” groups.

The term “alkoxy,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals include y, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert—butoxy, and the like.

The term “alkyl,” as used herein, alone or in combination, refers to a straight- chain or branched-chain saturated hydrocarbon containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, the alkyl will comprise from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, npropyl , isopropyl, n-butyl, yl, sec-butyl, tert—butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or ed chain saturated arbon attached at two or more positions, such as methylene (—CH2—). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.

The term “alkylamino,” as used herein, alone or in ation, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or lated, forming groups such as, for example, N-methylamino, N-ethylamino, methylamino, N,N—ethylmethylamino and the like.

The term “alkylidene,” as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.

The term “alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R—S—) l wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether radicals e methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, tylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.

The term “alkynyl,” as used herein, alone or in ation, refers to a straight— chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, the alkynyl comprises from 2 to 4 carbon atoms. The term ylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —CEC—). Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-l-yl, butynyl, pentyn-l-yl, 3-methylbutyn-l-yl, hexynyl, and the like. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.

The terms “amido” and moyl” as used herein, alone or in combination, refer to an amino group as bed below attached to the parent molecular moiety through a carbonyl group, or Vice versa. The term “C—amido” as used herein, alone or in combination, refers to a (RR’) group with R and R’ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R’)— group, with R and R’ as defined herein or as defined by the specifically enumerated “R” groups designated. The term "acylamino" as used herein, alone or in combination, embraces an acyl group attached to the parent moiety h an amino group. An example of an "acylamino" group is acetylamino (CH3C(O)NH—).

The term “amino,” as used herein, alone or in combination, refers to —NRR’, wherein R and R’ are independently ed from the group consisting of hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R’ may combine to form heterocycloalkyl, either of which may be optionally substituted.

The term "aryl," as used , alone or in combination, means a yclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term "aryl" embraces aromatic groups such as phenyl, yl, anthracenyl, and phenanthryl. [03 8] The term “arylalkenyl” or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group. [03 9] The term “arylalkoxy” or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group ed to the parent molecular moiety through an alkoxy group.

The term “arylalkyl” or “aralkyl,” as used herein, alone or in ation, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

The term “arylalkynyl” or ynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.

The term “arylalkanoyl” or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl—substituted alkanecarboxylic acid such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4- phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.

The term aryloxy as used herein, alone or in combination, refers to an aryl group ed to the parent molecular moiety through an oxy.

The terms “benzo” and “benz,” as used herein, alone or in combination, refer to the divalent radical C6H4: derived from benzene. Examples include benzothiophene and idazole‘ The term “carbamate,” as used herein, alone or in combination, refers to an ester of carbamic acid O—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.

The term “O—carbamyl” as used , alone or in combination, refers to a -OC(O)NRR’, group-with R and R’ as defined herein.

The term “N-carbamyl” as used , alone or in combination, refers to a ROC(O)NR’- group, with R and R’ as defined herein.

The term nyl,” as used herein, when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.

The term xyl” or “carboxy,” as used , refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein. A “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.

The term “cyano,” as used herein, alone or in combination, refers to —CN.

The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, the cycloalkyl will comprise from 5 to 7 carbon atoms. es of such lkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H— indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring s, such as decahydronaphthalene, dronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type WO 01426 of isomer is exemplified in general by, o[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.

The term “ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms.

The term “ether,” as used herein, alone or in ation, refers to an oxy group bridging two moieties linked at carbon atoms.

The term ” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.

The term “haloalkoxy,” as used herein, alone or in ation, refers to a haloalkyl group attached to the parent molecular moiety h an oxygen atom.

The term “haloalkyl,” as used herein, alone or in ation, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals e fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

“Haloalkylene” refers to ahaloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF2 —), chloromethylene (—CHCl—) and the like.

The term "heteroalkyl," as used herein, alone or in ation, refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, ting of the stated number of carbon atoms and from one to three heteroatoms selected from the group ting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3. [05 8] The term "heteroaryl," as used herein, alone or in combination, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or lic ring system in which at least one of the fused rings is aromatic, which contains at least one atom selected from the group consisting of O, S, and N. In certain embodiments, the heteroaryl will se from 5 to 7 carbon atoms. The term also es fused clic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, fuiyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, nolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, adiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, olopyridazinyl, tetrahydroisoquinolinyl, pyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.

The terms ocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or lic heterocyclic group containing at least one heteroatom as a ring member, n each the heteroatom may be independently selected from the group consisting of nitrogen, oxygen, and sulfur In certain embodiments, the heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In r embodiments, the heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, the heterocycloalkyl will comprise from 3 to 8 ring s in each ring. In further embodiments, the heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, the heterocycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, es of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an onal heterocycle group.

Examples of heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[l,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, oindolyl, dihydropyridinyl, 1,3- dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.

The term “hydrazinyl” as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., —N—N—.

The term “hydroxy,” as used herein, alone or in combination, refers to —OH.

The term “hydroxyalkyl,” as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

The term “imino,” as used herein, alone or in combination, refers to =N—.

The term “iminohydroxy,” as used herein, alone or in combination, refers to =N(OH) and =N—O—.

The phrase “in the main chain” refers to the longest contiguous or adjacent chain of carbon atoms ng at the point of attachment of a group to the compounds of any one of the formulas disclosed herein.

The term anato” refers to a —NCO group.

The term “isothiocyanato” refers to a —NCS group.

The phrase “linear chain of atoms” refers to the longest straight chain of atoms independently selected from carbon, en, oxygen and sulfur.

The term “lower,” as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms.

The term “lower aryl,” as used herein, alone or in ation, means phenyl or yl, either of which may be optionally substituted as provided.

The term “lower heteroaryl,” as used , alone or in combination, means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four the members may be heteroatoms selected from the group consisting of O, S, and N, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms selected from the group consisting of O, S, and N.

The term “lower cycloalkyl,” as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring s. Lower cycloalkyls may be unsaturated. es of lower cycloalkyl e cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “lower heterocycloalkyl,” as used herein, alone or in combination, means a monocyclic heterocycloalkyl having n three and six ring members, of which 2016/037213 between one and four may be heteroatoms selected from the group consisting of O, S, and N.

Examples of lower heterocycloalkyls e pyrrolidinyl, olidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl, Lower heterocycloalkyls may be unsaturated.

The term “lower amino,” as used herein, alone or in combination, refers to — NRR’, wherein R and R’ are independently selected from the group consisting of hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted. Additionally, the R and R’ of a lower amino group may combine to form a five- or six-membered heterocycloalkyl, either of which may be optionally substituted.

The term “mercaptyl” as used herein, alone or in combination, refers to an RS— group, where R is as defined herein.

The term “nitro,” as used herein, alone or in combination, refers to —N02.

The terms “oxy” or “oxa,” as used herein, alone or in combination, refer to —O—. [07 8] The term “oxo,” as used , alone or in combination, refers to =0.

The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are ed by halogen atoms.

The term “perhaloalkyl” as used , alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.

The terms “sulfonate,” “sulfonic acid,” and “sulfonic,” as used herein, alone or in combination, refer to the —SO3H group and its anion as the sulfonic acid is used in salt formation.

The term “sulfanyl,” as used herein, alone or in combination, refers to —S—.

The term “sulfinyl,” as used herein, alone or in combination, refers to —S(O)—.

The term “sulfonyl,” as used herein, alone or in combination, refers to —S(O)2—.

The term “N-sulfonamido” refers to a RS(=O)2NR’- group with R and R’ as defined .

The term “S-sulfonamido” refers to a 2NRR’, group, with R and R’ as defined herein.

The terms “thia” and “thio,” as used herein, alone or in ation, refer to a — 8— group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio.

The term “thiol,” as used herein, alone or in combination, refers to an —SH group.

The term “thiocarbonyl,” as used herein, when alone includes thioformyl —C(S)H and in ation is a —C(S)— group.

The term “trihalomethoxy” refers to a X3CO— group where X is a halogen.

Any definition herein may be used in combination with any other definition to describe a composite structural group. By tion, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group ed to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.

When a group is defined to be “null,” what is meant is that the group is absent.

The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without tion, one or more substituents ndently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower kyl, lower haloalkenyl, lower kynyl, lower , lower haloalkoxy, oxo, lower cyano, en, halogen, hydroxy, amino, lower alkylamino, amido, nitro, thiol, 3, C02CH3, and COzH, Where substituents are recited without qualification as to substitution, both substituted and tituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.” The term R or the term R’, appearing by itself and without a number designation, unless otherwise defined, refers to a moiety selected from the group consisting of hydrogen, alkyl, alkylene, alkynylene, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted as defined herein. Unless otherwise specified, when either R or R’ contains a heteroatom, they should be understood to attach to the parent group via a carbon atom. Whether an R group has a number designation or not, every R group, including R, R’ and Rn where n = (1, 2, 3 ...n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any variable, substituent, or term (e.g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is ndent of the definition at every other occurrence. Those of skill in the art will r recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. Thus, by way of example only, an unsymmetrical group such as — C(O)N(R)— may be attached to the parent moiety at either the carbon or the en.

Asymmetric centers exist in the compounds disclosed herein. These s are designated by the symbols “R” or S” ing on the ration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and ic forms, as well as d-isomers and l-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially ble ng materials which contain chiral centers or by preparation of es of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, en (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this disclosure. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.

In general, the solvated forms are considered equivalent to the unsolvated forms.

The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered part of larger substructure. A bond may be single, double, or triple unless ise specified. A dashed line between two atoms in a drawing of a le indicates that an additional bond may be present or absent at that position.

The term se” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder, )7 ccsyndrome,” and “condition” (as in l condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a ntially simultaneous , such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner.

In either case, the ent regimen will provide beneficial effects of the drug combination in treating the conditions or ers described herein.

MCT4 inhibitor is used herein to refer to a compound that exhibits an IC50 with t to MCT4 ty of no more than about 100 uM and more typically not more than about 50 nM, as measured in the MCT4 enzyme assay described generally herein below.

IC50 is that concentration of inhibitor that reduces the activity of an enzyme (e.g., MCT4) to half-maximal level. Certain compounds disclosed herein have been discovered to t inhibition against MCT4. In certain embodiments, compounds will exhibit an IC50 with respect to MCT4 of no more than about 10 nM, in further embodiments, compounds will exhibit an IC50 with respect to MCT4 of no more than about 5 nM, in yet further embodiments, compounds will exhibit an IC50 with respect to MCT4 of not more than about 1 nM, in yet further embodiments, compounds will exhibit an IC50 with respect to MCT4 of not more than about 200 nM, as measured in the MCT4 binding assay described .

The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.

The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a able benefit/risk ratio, and are effective for their intended use.

As used , reference to "treatment" of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. tion of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen, or may e prevention of disease ssion. For example, tion of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.

The term “patient” is generally mous with the term “subject” and includes all mammals ing humans. Examples of patients e humans, livestock (farm animals) such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

The term "prodrug" refers to a compound that is made more active in vivo.

Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug lism : try, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound.

Additionally, prodrugs can be ted to the compound by chemical or mical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a nd when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical itions over the parent drug. A wide y of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

The compounds disclosed herein can exist as therapeutically acceptable salts. The present disclosure includes nds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids.

Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the ation and purification of the compound in question. Basic addition salts may also be formed and be ceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, rland, 2002).

The term peutically acceptable salt,” as used , represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts e acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, ate, hemisulfate, oate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, te, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, e, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, ate, glutamate, bicarbonate, para-toluenesulfonate (p—tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides, dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and oric, and c acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present sure contemplates sodium, ium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or onate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic nary amine cations such as ammonium, ethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, larnine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, ylpiperidine, N—methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, l-ephenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, nolamine, dine, and piperazine.

A salt of a compound can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.

Compounds The present disclosure provides a nd of structural Formula I X W \A1_<’ Y/A\’?3,N2 \Z (I) or a salt thereof, wherein: A1, A2, and A3 are independently chosen from N and C, wherein at least one of A1, A2, and A3 is N, L is chosen from a bond and methylene; 0 0 \ o JL 3 OH \ )fi/OfikOH Wischosenfromjll OH, W felNkOH, R5R4 o o o WO%OCH3 Wowgsz )fi/OXkOH >0 5o 0“ R5R4 R5R4 and , 7 , 3 WO%N,SO2CH3 R5 R4 H X is chosen from alkenyl, alkenylamino, alkyl, aminoalkenyl, aminoalkyl, and H, any of which may be optionally substituted with one to three Rl groups, each independently chosen from alkyl, l, alkoxy, haloalkyl, haloalkoxy, alkylamino, amino, amido, amido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, Y is chosen from alkenyl, alkenylamino, alkyl, aminoalkenyl, aminoalkyl, aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, koxy, cycloalkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, wherein when X is not H, X and Y together with the atoms to which they are attached may form an aryl, lkyl, aryl, or heterocycloalkyl ring, any of which may be optionally substituted with one to three R7 groups each independently chosen from alkyl, alkenyl, alkoxy, kyl, haloalkoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, and R4 and R5 are independently chosen from H and alkyl, with R4 and R5 together having no more than 6 s; and Z is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, amino, amido, amido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, In certain embodiments, A1 and A2 are C; and A3 is N.

In certain embodiments, X is hydrogen.

In certain embodiments, W is chosen from: o o o o 0 \WWpvt ”MACH “fie moxie :‘aOH,\/ \ HH , OH, ,MeMe , MeEt, o o o Fi/O >00 OH >00 OH X/0 o NH2 )0 OH OCH3 Et Et Me Me Me Me 2 a , , ,and Wofistozm-Ig,H Me Me In certain embodiments, W is chosen from Pfi/OwgkOH NHZ X/0781\OCH3andX/ %NO ’30 CH2 3 R5 R4 H Me Me Me Me Me Me ;and R4 and R5 are independently chosen from H and alkyl, with R4 and R5 together having no more than 6 carbons.

In certain embodiments, X is chosen from alkenyl, alkenylamino, alkyl, lkenyl, aminoalkyl, and H, any of which may be optionally substituted with one to three Rl groups, each independently chosen from l, alkoxy, alkyl, aryl, halo, heteroaryl, and haloalkyl, Y is chosen from alkenyl, alkenylamino, alkyl, aminoalkenyl, arninoalkyl, aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkenyl, alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, aryl, halo, heteroaryl, and haloalkyl, wherein when X is not H, X and Y together with the atoms to which they are attached may form an aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring, any of which may be optionally substituted with one to three R4 groups each independently chosen from alkenyl, , alkyl, aryl, halo, heteroaryl, and haloalkyl; and Z is chosen from aryl and heteroaryl, either of which may be ally substituted with one to three R3 groups each independently chosen from alkenyl, alkoxy, alkyl, alkylamino, aryl, halo, heteroaryl, and haloalkyl.

In certain ments, Z is chosen from phenyl and pyridinyl, either of which may be optionally tuted with one to three R3 groups each independently chosen from alkenyl, alkoxy, alkyl, alkylamino, aryl, halo, heteroaryl, and haloalkyl.

In certain embodiments, Y is chosen from aryl and heteroaryl, any of which may be ally substituted with one to three R2 groups each independently chosen from alkenyl, alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, aryl, halo, heteroaryl, and haloalkyl.

In certain embodiments, Y is chosen from , thienyl, and thiazolyl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and kyl.

In certain ments, R4 and R5 are chosen from the following combinations: R4 and R5 are each methyl, R4 and R5 are each ethyl; and R4 is methyl and R5 is ethyl.

In certain embodiments, the compound has structural Formula II: L‘Z (II) or a salt thereof, wherein: L is chosen from a bond and methylene; O O O )fi/OVKOH F’i/ 78km2O Pfi/ 78kooH3O Wis chosen from R5 R4 Me Me Me Me , , ,and woflstozcmH Me Me ~ Y is chosen from aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each ndently chosen from alkyl, l, alkoxy, haloalkyl, haloalkoxy, cycloalkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, R4 and R5 are independently chosen from H and alkyl, with R4 and R5 er having no more than 6 carbons; and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkyl, alkenyl, , haloalkyl, haloalkoxy, alkylamino, amino, amido, amido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl.

In certain ments, Y is chosen from aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkenyl, alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, aryl, halo, heteroaryl, and haloalkyl, and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkenyl, alkoxy, alkyl, alkylamino, aryl, halo, heteroaryl, and haloalkyl.

In certain ments, Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkenyl, alkoxy, alkyl, alkylamino, aryl, halo, heteroaryl, and haloalkyl.

In certain embodiments, Y is chosen from phenyl, thienyl, and lyl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl.

In certain embodiments, R4 and R5 are chosen from the following combinations: R4 and R5 are each methyl, R4 and R5 are each ethyl; and R4 is methyl and R5 is ethyl.

In certain embodiments, the nd has structural Formula 111: R4 0R6 Z (111) or a salt thereof, wherein: L is chosen from a bond and methylene; R4 and R5 are independently chosen from H and alkyl, with R4 and R5 together having no more than 6 s; R6 is chosen from H and methyl; Y is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R2 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl; and Z is chosen from phenyl and pyridinyl, either of which may be optionally tuted with one to three R3 groups each ndently chosen from alkyl; alkenyl, alkoxy; haloalkyl, haloalkoxy, alkylamino, amino, amido, sulfonarnido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl.

Also ed are stereoisomers (e.g., enantiomers and diastereomers) of compounds disclosed herein. For example, in certain embodiments, also ed are compound of structural Formula IIIa or IIIb: CR6 R5 R4H R4 0R6 2 (111a) Z mm or a salt thereof, wherein: L is chosen from a bond and methylene; R4 and R5 are independently chosen from H and alkyl, with R4 and R5 together having no more than 6 carbons; R6 is chosen from H and methyl; Y is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R2 groups each independently chosen from alkyl, l, alkoxy, haloalkyl, haloalkoxy, lkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl, and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each ndently chosen from alkyl, alkenyl, , haloalkyl, koxy, alkylamino, amino, arnido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl.

In certain embodiments, Y is chosen from aryl and heteroaryl, either of which may be ally substituted with one to three R2 groups each independently chosen from alkenyl, alkoxy, lkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, aryl, halo, heteroaryl, and haloalkyl; and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkenyl, alkoxy, alkyl, alkylamino, aryl, halo, heteroaryl, and haloalkyl.

In certain embodiments, Y is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R2 groups each independently chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

In certain embodiments, Y is chosen from phenyl, thienyl, and thiazolyl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and kyl.

In certain embodiments, R4 and R5 are chosen from the following combinations: R4 and R5 are each methyl, R4 and R5 are each ethyl; and R4 is methyl and R5 is ethyl.

In certain embodiments, Y is phenyl, substituted with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is , substituted with one or two R3 groups chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

In certain embodiments, Y is ubstituted with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, and haloalkoxy.

In certain embodiments, Y is meta-substituted with an R2 group chosen from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, isopropoxy, oxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclopropylmethoxy, cyclobutylmethoxy, and cyclopentylmethoxy.

In certain embodiments, Z is ortho-substituted with an R3 group chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

In certain embodiments, Z is ortho-substituted with halo.

In certain ments, Z is ortho-substituted with chloro.

In certain embodiments, R6 is H.

In certain embodiments, Y is thienyl, substituted with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is phenyl, tuted with one or two R3 groups chosen from alkoxy, alkyl, mino, halo, and haloalkyl.

In certain embodiments, Y is substituted with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, and haloalkoxy.

In certain embodiments, Y is substituted with an R2 group chosen from methoxy, isopropoxy, isobutoxy, and cyclopropoxy.

In certain ments, Z is ortho-substituted with an R3 group chosen from alkoxy, alkyl, mino, halo, and haloalkyl.

In certain ments, Z is substituted with halo.

In certain embodiments, Z is ortho-substituted with chloro.

In certain embodiments, R6 is H.

In certain embodiments, Y is thiazolyl, substituted with one R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is phenyl, substituted with one or two R3 groups chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl. 2016/037213 In n embodiments, Y is substituted with one R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, and haloalkoxy.

In certain embodiments, Y is substituted with one R2 group chosen from methoxy, isopropoxy, isobutoxy, and ropoxy.

In certain embodiments, Z is ortho-substituted with one R3 group chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

In certain ments, Z is ortho-substituted with one halo.

In certain embodiments, Z is ortho-substituted with one chloro.

In certain embodiments, R6 is H.

In certain embodiments, the compound is chosen from Examples 1-82 or a salt thereof, as disclosed herein.

Also ed are embodiments wherein any of embodiment above in paragraphs and [0108] — [0149] above may be combined with any one or more of these embodiments, provided the combination is not mutually exclusive.

Pharmaceutical Compositions While it may be possible for the compounds of the subject disclosure to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation. Accordingly, ed herein are pharmaceutical ations which comprise one or more of certain compounds disclosed , or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates f, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other eutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper ation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington’s Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e,g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or ssion processes.

The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, gual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be ted in unit dosage form and may be ed by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound of the subject sure or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof ("active ingredient") with the carrier which tutes one or more accessory ients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Compounds described herein can be administered as follows: Oral Administration The compounds of the t invention may be administered orally, including swallowing, so the compound enters the intestinal tract, or is ed into the blood stream directly from the mouth, including sublingual or buccal administration. le compositions for oral administration include solid formulations such as tablets, pills, cachets, lozenges and hard or soft capsules, which can contain liquids, gels, powders, or granules.

In a tablet or capsule dosage form the amount of drug present may be from about 0.05% to about 95% by weight, more typically from about 2% to about 50% by weight of the dosage form.

In addition, tablets or capsules may contain a disintegrant, comprising from about 0.5% to about 35% by weight, more typically from about 2% to about 25% of the dosage form. Examples of disintegrants include methyl cellulose, sodium or calcium carboxymethyl cellulose, croscarmellose sodium, polyvinylpyrrolidone, hydroxypropyl cellulose, starch and the like, Suitable binders, for use in a tablet, include gelatin, polyethylene glycol, , gums, starch, hydroxypropyl cellulose and the like. le diluents, for use in a tablet, include mannitol, xylitol, lactose, dextrose, sucrose, sorbitol and starch.

Suitable surface active agents and glidants, for use in a tablet or capsule, may be t in amounts from about 0.1% to about 3% by , and include polysorbate 80, sodium dodecyl sulfate, talc and silicon dioxide.

Suitable lubricants, for use in a tablet or capsule, may be present in amounts from about 0.1% to about 5% by weight, and include calcium, zinc or ium stearate, sodium stearyl fumarate and the like.

Tablets may be made by compression or molding, ally with one or more accessory ingredients. Compressed tablets may be prepared by ssing in a suitable machine the active ingredient in a owing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing . Molded tablets may be made by g in a suitable machine a mixture of the powdered compound moistened with a liquid diluent. Dyes or pigments may be added to tablets for identification or to characterize different combinations of active compound doses.

Liquid formulations can include emulsions, solutions, syrups, elixirs and suspensions, which can be used in soft or hard capsules. Such formulations may include a pharmaceutically acceptable carrier, for example, water, ethanol, polyethylene glycol, cellulose, or an oil. The formulation may also include one or more emulsifying agents and/or suspending agents.

Compositions for oral administration may be formulated as immediate or modified release, including delayed or sustained e, optionally with enteric coating.

In another embodiment, a pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt f, and a pharmaceutically acceptable carrier.

Parenteral stration Compounds of the present ion may be administered directly into the blood stream, muscle, or internal organs by injection, e.g., by bolus injection or uous infusion. Suitable means for parenteral administration include intravenous, intra—muscular, subcutaneous intraarterial, intraperitoneal, intrathecal, intracranial, and the like. Suitable devices for parenteral administration include ors (including needle and needle-free injectors) and on methods. The formulations may be presented in ose or multi- dose containers, for example sealed ampoules and vials.

Most parenteral ations are aqueous solutions containing excipients, including salts, buffering, suspending, stabilizing and/or dispersing agents, antioxidants, bacteriostats, preservatives, and solutes which render the formulation isotonic with the blood of the intended recipient, and carbohydrates.

Parenteral formulations may also be ed in a dehydrated form (e.g., by lyophilization) or as sterile non-aqueous solutions. These formulations can be used with a suitable vehicle, such as sterile water. lity-enhancing agents may also be used in ation of parenteral solutions.

Compositions for parenteral administration may be formulated as immediate or modified release, including d or sustained release. Compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular ion. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Topical Administration Compounds of the present invention may be administered topically (for e to the skin, mucous membranes, ear, nose, or eye) or transdermally. ations for topical administration can include, but are not limited to, lotions, ons, creams, gels, hydrogels, ointments, foams, implants, patches and the like. Carriers that are pharmaceutically acceptable for topical administration formulations can include water, alcohol, mineral oil, in, polyethylene glycol and the like. Topical administration can also be performed by, for example, electroporation, iontophoresis, phonophoresis and the like.

Typically, the active ingredient for topical administration may se from 0.001% to 10% w/w (by weight) of the formulation. In n embodiments, the active ingredient may comprise as much as 10% w/w, less than 5% w/w; from 2% w/w to 5% w/w; or from 0.1% to 1% w/w of the formulation.

Compositions for topical stration may be formulated as immediate or modified release, including delayed or sustained release.

Rectal, Buccal, and Sublingual Administration Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or anth.

Administration by Inhalation For administration by inhalation, compounds may be iently delivered from an insufflator, nebulizer rized packs or other convenient means of delivering an aerosol spray or powder. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, rotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to r a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the disclosure may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder ition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

Other carrier materials and modes of administration known in the pharmaceutical art may also be used. ceutical compositions of the invention may be prepared by any of the well-known techniques of cy, such as effective formulation and administration procedures. Preferred unit dosage ations are those ning an effective dose, as herein recited, or an appropriate on thereof, of the active ingredient. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific nd employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise er being treated, and the ty of the indication or condition being treated. In addition, the route of administration may vary depending on the condition and its severity. The above considerations concerning effective formulations and administration procedures are well known in the art and are described in standard textbooks.

Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1975, Liberman, et al., Eds, Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980, and Kibbe, et al., Eds, Handbook of Pharmaceutical Excipients (3rd Ed), American Pharmaceutical Association, Washington, 1999.

Accordingly, also provided herein is a pharmaceutical composition comprising a compound as disclosed , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle, In certain embodiments, the pharmaceutical composition is formulated for oral administration In certain embodiments, the pharmaceutical composition is formulated for parenteral administration. In certain embodiments, the pharmaceutical composition is formulated for intravenous stration.

Methods of Receptor Modulation and Treatment The present disclosure provides compounds and pharmaceutical itions that inhibit glutaminase activity, particularly MCT4 ty and are thus useful in the treatment or tion of disorders associated with MCT4. Compounds and pharmaceutical compositions of the present disclosure ively modulate MCT4 and are thus useful in the treatment or prevention of a range of disorders associated with MCT4 and include, but are not d to, proliferative and inflammatory diseases.

Accordingly, provided herein is a method for inhibiting activity of the rboxylate transporter MCT4, or a mutant f, in a biological sample comprising the step of contacting said biological sample with a compound as disclosed herein, or a salt thereof Also provided herein is a method for ting activity of the monocarboxylate transporter MCT4, or a mutant thereof, in a patient comprising the step of administering to the t a compound as disclosed herein, or a salt thereof.

Also ed herein is a method for selectively inhibiting activity of the monocarboxylate transporter MCT4, or a mutant thereof, over the monocarboxylate transporter MCT1, or a mutant thereof, in a t comprising the step of administering to the patient a compound as disclosed herein, or a salt thereof.

In certain embodiments, the inhibition is at least 100-fold selective for MCT4 over MCTl. 2016/037213 Cancer In certain embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful in the treatment or prevention of cancer.

In n embodiments, the compounds of the present disclosure may be used to prevent or treat cancer, wherein the cancer is one or a t of Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, AIDS- Related Cancers (Kaposi Sarcoma and Lymphoma), Anal Cancer, Appendix Cancer, Atypical Teratoid/Rhabdoid Tumor, Basal Cell oma, Bile Duct Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including Osteosarcoma and Malignant Fibrous Histiocytoma), Brain Tumor (such as Astrocytomas, Brain and Spinal Cord Tumors, Brain Stem Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, l Nervous System Embryonal Tumors, Craniopharyngioma, Ependymoblastoma, Ependymoma, Medulloblastoma, Medulloepithelioma, Pineal Parenchymal Tumors of Intermediate Differentiation, Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma), Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Basal Cell Carcinoma, Bile Duct Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including Osteosarcoma and ant Fibrous Histiocytoma), Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System (such as Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumors and Lymphoma), Cervical Cancer, Childhood Cancers, Chordoma, Chronic cytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative ers, Colon Cancer, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma (Mycosis Fungoides and Se’zary Syndrome), Duct, Bile (Extrahepatic), Ductal oma In Situ (DCIS), Embryonal Tumors al Nervous System), Endometrial Cancer, Ependymoblastoma, moma, Esophageal Cancer, Esthesioneuroblastoma, Ewing Sarcoma Family of Tumors, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer (like Intraocular Melanoma, Retinoblastoma), Fibrous Histiocytoma of Bone (including Malignant and Osteosarcoma) Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors , Germ Cell Tumor (Extracranial, onadal, Ovarian), ional blastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck , Heart Cancer, cellular (Liver) Cancer, Histiocytosis, Langerhans Cell, Hodgkin Lymphoma, Hypopharyngeal , Intraocular Melanoma, Islet Cell Tumors (Endocrine, Pancreas), Kaposi Sarcoma, Kidney (including Renal Cell), Langerhans Cell Histiocytosis, Laryngeal Cancer, Leukemia (including Acute Lymphoblastic (ALL), Acute Myeloid (AML), Chronic Lymphocytic (CLL), Chronic Myelogenous (CML), Hairy Cell), Lip and Oral Cavity Cancer, Liver Cancer (Primary), Lobular oma In Situ , Lung Cancer (Non-Small Cell and Small Cell), Lymphoma (AIDS-Related, t, Cutaneous T-Cell (Mycosis Fungoides and Se’zary Syndrome), Hodgkin, Non-Hodgkin, Primary Central Nervous System (CNS), Macroglobulinemia, Waldenstrom, Male Breast Cancer, Malignant Fibrous Histiocytoma of Bone and arcoma, Medulloblastoma, Medulloepithelioma, Melanoma (including Intraocular , Merkel Cell Carcinoma, Mesothelioma (Malignant), Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Myeloid Leukemia, Acute (AML), Myeloma and Multiple Myeloma, Myeloproliferative Disorders (Chronic), Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, lastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer, Lip and, Oropharyngeal Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma of Bone, Ovarian Cancer (such as Epithelial, Germ Cell Tumor, and Low Malignant Potential Tumor), Pancreatic Cancer ding Islet Cell Tumors), Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumors of ediate Differentiation, Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary ma, Pregnancy and Breast Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal Cancer, Renal Cell (Kidney) Cancer, Renal Pelvis and Ureter, Transitional Cell Cancer, blastoma, Rhabdomyosarcoma, Salivary Gland Cancer, a (like Ewing a Family of , Kaposi, Soft Tissue, Uterine), Se’zary Syndrome, Skin Cancer (such as Melanoma, Merkel Cell Carcinoma, Nonmelanoma), Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Cell oma, Squamous Neck Cancer with Occult y, Metastatic, Stomach (Gastric) Cancer, Supratentorial Primitive Neuroectodermal Tumors, T—Cell ma (Cutaneous, Mycosis Fungoides and Sézary me), Testicular Cancer, Throat Cancer, Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Trophoblastic Tumor (Gestational), Unknown Primary, Unusual Cancers of Childhood, Ureter and Renal Pelvis, Transitional Cell Cancer, Urethral Cancer, Uterine Cancer, Endometrial, Uterine Sarcoma, strém Macroglobulinemia or Wilms Tumor.

In certain ments, the cancer to be d is one specific to T-cells such as T—cell lymphoma and lymphoblastic T-cell leukemia.

In certain embodiments, the nds and pharmaceutical compositions of the present disclosure may be useful in the treatment or prevention of an inflammatory disease.

In certain embodiments, methods described herein are used to treat a disease condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of aI or ceutically acceptable salt thereof, wherein the condition is cancer which has developed resistance to chemotherapeutic drugs and/or ng radiation.

Inflammatory Disease In certain embodiments, the compounds and ceutical itions of the present disclosure may be useful in the treatment or prevention of inflammatory e.

In certain embodiments, the compounds of the present sure may be used to prevent or treat inflammatory disease, wherein the inflammatory disease is one or a variant of acid-induced lung injury, acne (PAPA), acute respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, ageing, AIDS, lic hepatitis, alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's e, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, anhidrotic ectodermal dysplasia (eg. with immune deficiency), ankylosing spondylitis, anterior segment inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune hepatitis, bee sting-induced inflammation, Behcet's e, Bell’s Palsy, berylliosis, Blau syndrome, bone pain, bronchiolitis, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, catabolic disorders, cataracts, cerebral aneurysm, chemical nt-induced inflammation, retinitis, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, connective tissue disease, corneal ulcer, Crohn's disease, cryopyrin— associated periodic syndromes, cryptococcosis, cystic s, deficiency of the interleukin- 1—receptor nist, dermatitis, dermatitis endotoxemia, dermatomyositis, endometriosis, endotoxemia, epicondylitis, erythroblastopenia, familial amyloidotic polyneuropathy, familial cold urticaria, familial Mediterranean fever, fetal growth retardation, glaucoma, glomerular disease, glomerular nephritis, gout, gouty tis, graft-versus-host disease, gut diseases, head injury, he, hearing loss, heart e, hemolytic anemia, Henoch-Scholein purpura, tis, hereditary periodic fever me, herpes zoster and simplex, HIV-l, Huntington's disease, e membrane disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever, hypoplastic and other anernias, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, incontinentia pigmenti, infectious cleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, atory pain, insect bite-induced inflammation, iritis, ischemia/reperfusion, juvenile rheumatoid arthritis, keratitis, kidney disease, kidney injury caused by parasitic infections, kidney transplant rejection laxis, leptospirosis, Loeffler’s syndrome, lung , lupus, lupus nephritis, meningitis, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis, myocarditis, s fungoides, myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological es, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant, osteoarthritis, otitis media, Paget's disease, pain, pancreatitis, Parkinson's disease, pemphigus, pericarditis, periodic fever, periodontitis, pertussis, perineal or peritoneal triosis, pharyngitis and adenitis (PFAPA syndrome), plant irritant- induced inflammation, pneumocystis infection, pneumonia, pneumonitis, poison ivy/urushiol oil-induced inflammation, polyarteritis nodosa, polychondritis, stic kidney disease, polymyositis, psoriasis, psychosocial stress disease, ary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic sterile arthritis, renal e, retinal disease, rheumatic disease, rheumatoid arthritis, rheumatic carditis, sarcoidosis, sebborrhea, sepsis, severe pain, sickle cell, sickle cell anemia, silica-induced diseases, n’s syndrome, skin diseases, sleep apnea, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid hage, sunburn, systemic sclerosis (scleroderma), temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue transplant, TNF or associated periodic me (TRAP S), Toxoplasmosis, lant, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticaria, uveitis, Wegener's granulomatosis, and weight loss.

A method for treating a monocarboxylate orter ediated disorder in a subject in need thereof, comprising the step of stering to said patient a compound as disclosed herein, or a pharmaceutically able salt thereof.

In certain embodiments, the subject is a human.

In certain embodiments, the moncarboxylate orter MCT4-mediated disorder is chosen from an inflammatory disorder and a proliferative disorder.

In certain embodiments, the moncarboxylate transporter ediated disorder is a proliferative disorder.

In certain embodiments, the proliferative disorder is cancer.

In certain embodiments, the cancer is chosen from adenocarcinoma, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast , brain , carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, , gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's ma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic , pharyngeal , renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T—cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, e cancer, vaginal cancer, and Wilms' tumor.

In certain embodiments, the moncarboxylate transporter MCT4-mediated er is an inflammatory disorder.

In certain embodiments, the inflammatory disorder is chosen from Crohn’s disease, ulcerative colitis, idiopathic pulmonary fibrosis, muscular phy, rheumatoid arthritis, and systemic sclerosis (scleroderma).

Also provided herein is a method of treating a monocarboxylate orter MCT4-mediated disorder in a subject in need thereof, comprising the sequential or co- administration of a compound as disclosed herein or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

In n embodiments, the therapeutic agent is a protein kinase inhibitor.

In n embodiments, the protein kinase inhibitor is chosen from Aurora B, EGFR, PLK-l , CDKs inhibitors.

WO 01426 In certain embodiments, the eutic agent is chosen from an antimetabolite, bcr-abl inhibitor, DNA damaging agent, EGFR inhibitor, ubule stabilizing inhibitor, c arrest inhibitor, S-phase inhibitor, and a taxane.

In certain embodiments, the therapeutic agent is a DNA damaging agent chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, DNA replication inhibitor, intercalator, microtubule tor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

In certain embodiments, the therapeutic agent is chosen from aminoglutethimide, amsacrine, anastrozole, ginase, barasertib, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, trol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, ecan, ecan, ole, leucovorin, leuprolide, sole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, er, procarbazine, raltitrexed, rituXimab, sorafenib, streptozocin, nib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, Vinblastine, Vincristine, Vindesine, and Vinorelbine.

In certain embodiments, the method further ses administering non— chemical methods of cancer treatment.

In certain embodiments, the method further comprises administering radiation In certain embodiments, the method further comprises administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof.

Also ed herein is a compound as disclosed herein, or a pharmaceutically able salt thereof, for use in human therapy.

Also provided herein is a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for use in treating a monocarboxylate transporter MCT4-mediated disorder, for example as disclosed in any of the embodiments and aphs above pertaining to methods of treatment.

Also provided herein is the use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for the cture of a medicament to treat a monocarboxylate transporter MCT4-mediated disorder, for example as disclosed in any of the embodiments and paragraphs above pertaining to methods of treatment.

Combinations and Combination Therapy The compounds of the present invention can be used, alone or in combination with other pharmaceutically active compounds, to treat ions such as those previously described hereinabove. The compound(s) of the t invention and other pharmaceutically active compound(s) can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Accordingly, in one embodiment, the present invention comprises methods for treating a condition by administering to the subject a eutically-effective amount of one or more compounds of the present invention and one or more onal pharmaceutically active compounds.

In another ment, there is provided a pharmaceutical composition comprising one or more compounds of the present ion, one or more additional pharmaceutically active compounds, and a pharmaceutically acceptable carrier.

In another embodiment, the one or more additional pharmaceutically active compounds is selected from the group consisting of anti-cancer drugs, anti-proliferative drugs, and anti-inflammatory drugs.

MCT4 inhibitor compositions described herein are also optionally used in combination with other therapeutic reagents that are selected for their therapeutic value for the condition to be treated. In general, the compounds described herein and, in ments where combination therapy is employed, other agents do not have to be administered in the same pharmaceutical composition and, e of different physical and chemical characteristics, are optionally administered by different . The initial administration is generally made according to established protocols and then, based upon the observed effects, the dosage, modes of administration and times of administration subsequently modified. In certain instances, it is appropriate to administer a MCT4 inhibitor nd, as described herein, in combination with another eutic agent, By way of example only, the therapeutic effectiveness of a MCT4 inhibitor is ed by administration of another therapeutic agent (which also includes a therapeutic regimen) that also has eutic benefit. Regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient is either simply ve of the two therapeutic agents or the patient experiences an enhanced (i.e., synergistic) benefit. Alternatively, if a compound disclosed herein has a side effect, it may be appropriate to administer an agent to reduce the side effect; or the therapeutic effectiveness of a compound described herein may be enhanced by administration of an adj uvant.

Therapeutically effective dosages vary when the drugs are used in treatment ations. Methods for experimentally determining eutically effective s of drugs and other agents for use in ation treatment regimens are nted methodologies. ation treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient. In any case, the multiple therapeutic agents (one of which is a MCT4 inhibitor as described herein) may be administered in any order, or simultaneously. If simultaneously, the multiple therapeutic agents are ally ed in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills).

In certain embodiments, one of the therapeutic agents is given in multiple doses, or both are given as multiple doses. If not simultaneous, the timing between the multiple doses optionally varies from more than zero weeks to less than twelve weeks.

In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents, the use of multiple therapeutic combinations are also envisioned. It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is , is optionally modified in accordance with a variety of s. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, the dosage regimen ly employed varies widely, In certain embodiments, and therefore deviates from the dosage regimens set forth herein.

The pharmaceutical agents which make up the ation therapy disclosed herein are optionally a combined dosage form or in separate dosage forms intended for substantially simultaneous administration. The pharmaceutical agents that make up the combination therapy are optionally also administered sequentially, with either agent being administered by a regimen calling for two—step administration. The two-step administration regimen optionally calls for tial administration of the active agents or spaced-apart stration of the separate active agents. The time between the le administration steps ranges from a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the ceutical agent.

In another embodiment, a MCT4 inhibitor is optionally used in ation with procedures that provide additional benefit to the patient. A MCT4 tor and any additional therapies are optionally stered , during or after the occurrence of a disease or condition, and the timing of administering the composition containing a MCT4 inhibitor varies in some embodiments. Thus, for example, a MCT4 inhibitor is used as a prophylactic and is administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. A MCT4 inhibitor and compositions are ally administered to a subject during or as soon as possible after the onset of the symptoms. While embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and tutions will now occur to those skilled in the art without departing from the invention, It should be understood that in some embodiments of the invention s alternatives to the embodiments described herein are employed in practicing the ion.

A MCT4 inhibitor can be used in combination with anti-cancer drugs, including but not limited to the following classes: alkylating agents, anti-metabolites, plant alkaloids and terpenoids, topoisomerase inhibitors, cytotoxic antibiotics, angiogenesis inhibitors and tyrosine kinase tors.

For use in cancer and neoplastic diseases a MCT4 inhibitor may be optimally used together with one or more of the following non—limiting examples of ancer agents: (1) alkylating agents, including but not limited to tin (PLATIN), carboplatin (PARAPLATIN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), busulfan (MYLERAN) and cyclophosphamide (ENDOXAN), (2) anti-metabolites, including but not limited to mercaptopurine (PURINETHOL), anine, pentostatin (NIPENT), cytosine arabinoside (ARA-C), gemcitabine R), fluorouracil (CARAC), leucovorin (FUSILEV) and methotrexate (RHEUMATREX); (3) plant alkaloids and terpenoids, including but not limited to vincristine (ONCOVIN), vinblastine and paclitaxel (TAXOL), (4) omerase inhibitors, including but not limited to irinotecan (CAMPTOSAR), topotecan (HYCAMTIN) and etoposide (EPOSIN); (5) cytotoxic antibiotics, including but not limited to actinomycin D (COSMEGEN), doxorubicin (ADRIAMYCIN), bleomycin XANE) and mitomycin OL), (6) angiogenesis inhibitors, including but not limited to sunitinib T) and bevacizumab IN), and (7) tyrosine kinase inhibitors, including but not limited to imatinib EC), erlotinib (TARCEVA), lapatininb (TYKERB) and axitinib (INLYTA).

Where a t is suffering from or at risk of ing from an inflammatory condition, a MCT4 inhibitor compound described herein is optionally used together with one or more agents or methods for treating an inflammatory condition in any combination.

Therapeutic agents/treatments for treating an autoimmune and/or inflammatory condition include, but are not limited to any of the ing examples: (1) corticosteroids, including but not limited to one, dexamethasone, and methylprednisolone; (2) nonsteroidal anti- inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen (NALFON), flurbiprofen (ANSAID), ofen, oxaprozin (DAYPRO), diclofenac sodium (VOLTAREN), diclofenac potassium LAM), etodolac (LODINE), indomethacin (INDOCIN), ketorolac (TORADOL), sulindac (CLINORIL), tolmetin (TOLECTIN), meclofenamate (MECLOMEN), mic acid (PONSTEL), nabumetone (RELAFEN) and piroxicam (FELDENE); (3) immunosuppressants, including but not limited to methotrexate (RHEUMATREX), leflunomide (ARAVA), azathioprine (IMURAN), cyclosporine (NEORAL, SANDIMMUNE), tacrolimus and cyclophosphamide (CYTOXAN); (4) CD20 blockers, including but not limited to rituximab AN); (5) Tumor Necrosis Factor (TNF) blockers, including but not limited to etanercept L), infliximab (REMICADE) and adalimumab (HUMIRA), (6) interleukin-1 receptor antagonists, ing but not limited to anakinra ET), (7) interleukin-6 inhibitors, including but not limited to tocilizumab RA), (8) interleukin-l7 inhibitors, including but not limited to AIN457, (9) Janus kinase inhibitors, including but not limited to tasocitinib; and (10) syk inhibitors, including but not limited to fostamatinib.

Accordingly, also provided herein is a method of treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof, comprising the sequential or co-administration of a compound as disclosed herein or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

In certain embodiments, the eutic agent is a protein kinase inhibitor, 2016/037213 In certain embodiments, the protein kinase inhibitor is chosen from Aurora B, EGFR, PLK-l, CDKs inhibitors.

In certain embodiments, the therapeutic agent is chosen from an antimetabolite, bcr-abl inhibitor, DNA damaging agent, EGFR inhibitor, microtubule stabilizing inhibitor, mitotic arrest inhibitor, S-phase inhibitor, and a taxane.

In certain embodiments, the therapeutic agent is a DNA damaging agent chosen from an alkylating agent, anthracycline, tabolite agent, inking agent, DNA replication inhibitor, intercalator, microtubule disruptor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

In certain ments, the therapeutic agent is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, tabine, carboplatin, carmustine, chlorambucil, chloroquine, tin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, oxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, fllgrastim, fludarabine, ortisone, fluorouracil, esterone, flutamide, gemcitabine, genistein, goserelin, yurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, onate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituXimab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, Vinblastine, Vincristine, Vindesine, and Vinorelbine.

In certain embodiments, the method further comprises administering non- chemical methods of cancer treatment.

In certain embodiments, the method further comprises administering ion therapy.

In n ments, the method further comprises administering surgery, thermoablation, d ultrasound therapy, cryotherapy, or any ation thereof.

WO 01426 Compound Synthesis Compounds of the present invention can be prepared using s illustrated in general synthetic schemes and experimental procedures ed below. General synthetic schemes and experimental procedures are presented for purposes of illustration and are not intended to be limiting. Starting materials used to prepare compounds of the present invention are commercially available or can be prepared using routine methods known in the art.

List of Abbreviations CD3OD = deuterated ol; CDCl3 = deuterated chloroform; DCM = dichloromethane; DMF = N;N-dimethylformamide; h = hour; LAH = lithium aluminum hydride; MeOH = methanol; RT = room temperature; sat, = saturated; and THF = tetrahydrofuran. nds and General s for Preparing Them The following schemes can be used to practice the present invention. Additional structural groups, including but not limited to those defined elsewhere in the specification and not shown in the compounds described in the schemes can be incorporated to give various nds disclosed herein; or ediate compounds which can; after r manipulations using techniques known to those skilled in the art; be converted to compounds of the present invention. Examples shown below further illustrate the invention.

General Synthetic Scheme for Pyrazoles H0/ o 0/ OH / )N _) / \N _, / R100 [\N N R100 N, R100 N R101 R101 R103 0 R103 0 The general scheme above may be use to prepare nds disclosed herein. In the scheme as depicted; R100-R103 will be understood by one of skill in the art to be any WO 01426 2016/037213 appropriate group. For example, in certain embodiments, R100 and R101 may be independently chosen from aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, any of which may be optionally substituted. Likewise, in certain embodiments, R102 and R103 may be independently chosen from hydrogen, alkyl, and halogen. R100-R103 may also correspond to the groups defined in a I, II, or any other formula disclosed herein.

Synthetic Scheme for 2-[[1—[(3-chlorophenyl)methyl]phenyl-pyrazolyl]methoxy]—2- methyl-propanoic acid 0 O / / o o OH / \N _. / \N _, / \N H 53 CI 53 O 0— HO o OH / \ ,N / _> N ,N —> N 053 .53 Example 1: 2- [[1- [(3-Chl0r0phenyl)methyl]phenyl-pyrazol-3—yl]methoxy]methyl- propanoic acid. (1) Methyl 1-[(3-chlor0phenyl)methyljphenyl-pyrazolecarb0xylate._ To a suspension of methyl 5-phenyl-lH-pyrazolecarboxylate (l) (1.0 g, 4.94 mmol) in toluene was added NaH (60%) (0.394 g, 9.88 mmol) portionwise under N2 at room temperature, and stirring was continued for 30 min. To the above mixture a solution of 3-chlorobenzyl e (0.96 n11, 7.42 mmol) in toluene (3 mL) was added dropwise at 60 0C. The reaction mixture was d at 110 0C for 16 h. The mixture was cooled to room temperature and quenched with aq. NH4Cl solution. The mixture was partitioned with EtOAc (100 mL) and the organic layer was separated. The EtOAc layer was washed with brine (2x25 mL) and dried over Na2SO4, and the solvent was evaporated. The residue was chromatographed over SiO2 (ISCO CombiFlash® Rf200) using 0-50% nt of EtOAc in hexane to afford title compound (1.2 g, 75%). 1H NMR (CDC13, 400 MHz) 5 3.95 (s, 3H), 5.36 (s, 2H), 6.85-6.92 (m, 2H), .99 (m, 1H), 7.17-7.29 (m, 4H). 7.35-7.48 (m, 3H). (ii) [1-[(3-Clzl0r0phenyl)methyl]—5—phenyl—pyrazol—3—yl]methanol. A solution of methyl 1-[(3-chlor0plzenyl)methyl]—5-phenyl-pyrazolecarb0xylate (0.80 g, 2.45 mmol) in anhydrous THF was cooled to 0 0C. To the above mixture LAH (0.14g, 3.67 mmol) was added portionwise, and stirring was continued at 0 °C for 1.30 h. The mixture was quenched with water (0.15 mL) and 30% aq. NaOH solution (0.3 mL) at 0°C, and stirring was continued for 30 min. The reaction mixture was filtered, the filter cake was washed with THF (2x 10 mL), and the filtrates were combined and evaporated to dryness. The residue was chromatographed over SiO2 (ISCO CombiFlash® Rf200) using 0-40% nt of EtOAc in DCM to afford the title product (0.58 g 79%). 1H NMR (CDCl3, 400 MHz) 5 4.64-4.81 (d, 2H), 5.31 (s, 2H), 6.35 (s, 1H), 6.86-6.94 (n1, 1H), 6.98-7.05 (m, 1H), 7.19-7.23 (m, 2H), .35 (m, 2H), 7.39-7.46 (m 3H). (iii) Methyl 2-[[1-[(3—cl2lorophenyUmetlzyl]—5—plzenyl—pyrazol—S-yljmethoxyj-Z- methyl— propanoate. To a solution of [1-[(3-chlorophenyl)methyl]phenyl-pyrazol yl]methanol (0.288 g, 0.964 mmol) DMF was added NaH (60%) (0.077 g, 1.93 mmol) portionwise under N2 at room temperature, and stirring was continued for 30 min. The mixture was cooled to 0 °C and methyl 2-bromomethyl-propanoate (0.16 mL, 1.25 mmol) was added se followed by Nal (0.143 g, 0.964 mmol). The reaction mixture was warmed to room temperature gradually and stirred ght. At the end of this period aq.

NH4Cl solution was added, and the mixture was partitioned with EtOAc (40 mL). The aqueous layer was extracted with EtOAc (2x 20 mL). The combined EtOAc layers were washed with brine and dried over , and the solvent was evaporated. The residue was chromatographed over Si02 (ISCO CombiFlash® Rf200) using 0-50% gradient of EtOAc in hexanes to afford the title product as an oil (0.068 g, 38%). 1H NMR (CDCl3, 400 MHz): 8 1.56 (s, 6H). 3.68 (s, 3H), 4.58 (s, 2H), 5.25 (s, 2H), 6.45 (s, 1H), 6.87-6.93 (m, 1H), 7.00 (s, 1H), 7.16-7.22 (m, 2H), 7.26-7.34 (m, 2H), 7.34-7.42 (m, 3H). (iv) 2-[[1-[(3-Ch10r0phenyl)methyU—5-phenyl—pyrazol—3-yl]meth0xy]—2-methyl— propanoic acid. To a solution of 2-[[1-[(3-chlorophenyl)methyl]phenyl-pyrazolyl]- methoxy]methy1-propanoate (0.068 g, 0.170 mmol) in a e of THF, MeOH, H20 (2:111) (8 mL) was added lithium hydroxide monohydrate (0.035 g, 0.85 mmol) at RT and ng was continued for further 3h. At the end of this period the t was evaporated and to the residue water (2mL) was added and acidified with 1M citric acid. The mixture was ioned with EtOAc (25 mL) and washed with water (10 mL) followed by brine (10 mL).

The EtOAc layer was dried over Na2S04, and solvent was removed by evaporation. The crude product was chromatographed over Si02 (ISCO CombiFlash® Rf200) using 0-30% gradient of MeOH in DCM to afford the title product as white solid (0.032 g). 1HNMR(CDC13): 5 1.56(s, 6H), 4.61 (s, 2H), 5.34 (s, 2H), 6.38(s, 1H), 6.87-6.97(m, 1H), 7.04(s, 1H), 718-724(m, 2H), 7.26-7.35(m, 2H), 7.35-7.45(m, 3H).

Examples 2-50 were prepared analogously as described in Example 1.

Table 1 Exaanle Structure IUPAC Name and Analytical data 2-[[5-(4-Chlorophenyl)- l -[(4- chlorophenyl)methyl]pyrazol yl]methoxy]methyl-propanoic acid 1H NMR (CD3OD, 400 MHz) 8 , 6H), 4.54(s, 2H0, 5.329s, 2H), 6.48(s, 1H), 6.91-7.00(m, 1H), 7.21-7.30-(m, 2H), 7.31-7.38(m, 2H), 7.40-7.48 (m 3H).

§L\<O H 2-[[5-(4-Chloropheny1)[(2- o o ch10r0pheny1)methy1]pyrazol hoxy]methy1-pr0pan0ic acid N/ 1H NMR (CD3OD, 400 MHz) 5 1.50(s, 0' 6H), 4.58(s, 2H), 541(5, 2H), 656(s, 1H), 6.72-6.80 (m, 1H), 7.20-7.34(m, 2H), 7.34—50 (m, 5H). 2-[[1-[(2-Ch10rophenyl)methyl](4- fluoropheny1)pyraz01yl]methoxy] methyl-propanoic acid 1H NMR (CD3OD, 400 MHz) 81.51(s, 6H), 4.58(s, 2H), 5.40(s, 2H), 6.55(s, 1H), 6.70-6.78(m, 1H), 7.14—7.18(m, 2H), 7—20— 7.29(m, 2H), .40(m, 3H). 2-[[5-(4-Ch10rophenyl)[(2,4— dichlorophenyl)methyl]pyrazol—3- hoxy]methy1—pr0pan0ic acid 1H NMR (CD3OD, 400 MHz) 5 1.48(s, 6H), 4.58(s, 2H), 5.40 (s, 2H), 6.54(s, 1H), 6.73(d, 1H), 7.20-7.38 (m, 3H), 7.40-48 (m, 3H). 2-[[5-(4-Chlor0pheny1)[(2,4- dichlorophenyl)methyl]pyrazol yl]methoxy] acetic acid 1H NMR (DMSO-de, 400 MHz) 5 3.80 (s, 2H), 4.50 9s, 2H), 5.30 (s, 2H), 6.50 (s, 1H), 6.60-80 (m, 1H), 7.20—70 (m, 6H).

O O 2-[[1-Benzy1(4-Chlor0phenyl)pyrazol- 3-y1]methoxy]methy1-propan0ic acid N' 1H NMR (CD3OD, 400 MHz) 5 1.53(s, 0' 6H), 4.58(s, 2H), 5.38 (s, 2H), , 1H), 6.90(d, 2H), 7.18-7.50 (m, 7H). 2-[[1-[(2-Ch10rophenyl)methyl]pheny1- pyrazolyl]methoxy]—2-methy1- propanoic acid 1H NMR (DMSO-ds, 400 MHz) 51.56 (s, 6H), 4.58(s, 2H), 5.41(s, 2H), 656(s, 1H), 675-678(m, 1H), 7.20-7.30 (m, 4H), 7.32-7.43(m, 4H). 1H NMR (CD30D, 400 MHz) 5 1.54(s, 6H), 4.589s, 2H), , 2H), , 1H), 6.68-6.74(m, 1H), 7.20-7.42(m 8H). 2-[[5-(2-Chlorophenyl)[(2- pheny1)methy1]pyrazol yl]methoxy] methy1—pr0pan0ic acid 1H NMR (CD3OD, 400 MHz) 5 1.53(s, 6H), 458(s, 2H), 528(5, 2H), 6.43(s, 1H), 6.78-7.81(m, 1H), 7.16-34(m, 5H), 7.38- 7.42 (m, 1H), 7.50-7.56(m, 1H). 2-[[5-(3-Chloropheny1)[(2- chlorophenyl)methyl]pyrazol yl]methoxy] methy1—pr0pan0ic acid 1H NMR (CD3OD, 400 MHz) 51.32 (S, 6h)4.58(s, 2H), 5.42(s, 2H), 6.57(s, 1H), 6.67-6.80 (m, 1H), 7.22-7.30 (m, 3H), 7 .32-42(m, 4H). 2-[[1-[(2-Chlorophenyl)methyl](mt01y1 )pyrazoly1]methoxy]methy1- oic acid / \ 1H NMR (CDC13, 400 MHz) 8 1.58 (s, 11 N 6H), 2.35 (s, 3H), 4.61 (s, 2H),5.42 (s, 2H), 6.39 (s, 1H), 6.75-6.84 (m,1H), 7.00- 7.12 (m, 2H), 7.18-7.29 (4H), .38 (m, 1H). 2-[[1-[(2-Ch10rophenyl)methyl](3- fluoropheny1)pyraz01yl]methoxy] methyl-propanoic acid 1H NMR (CDC13, 400 MHz) 8 , 6H), 4.64 (s, 2H), 5.48 (s, 2H), 6.42 (s, 1H), 6.72-6.85 (m, 1H), 6.88-7.14 (m, 3H), 7.14-7.40 (m, 4H). 2-[[1-[(2-Ch10r0phenyl)methyl][3- (trifluoromethyl)phenyl]pyraz01 y1]methoxy]methy1—propan0ic acid 13 1H NMR (CDC13, 400 MHz) 5 1.58 (s, 6H), 4.62 (s, 2H), 5.41 (s, 2H), 6.46 (s, 1H), 6.80-6.88 (m,1H), .24(m, 2H), 7.29-7.38 (m, 1H), 7.39-7.47 (m,1H), 7.49-7.54 (m, 2H), 7.59-7.68 (m,1H). 2-[[1-[(2-Chlorophenyl)methyl](3- methoxyphenyl)pyrazol-3 -y1]methoxy] methyl—propanoic acid 14 1H NMR (CDC13, 400 MHz) 8 1.58 (s, 6H), 3.68 (s, 3H), 4.62 (s, 2H), 5.46 (s, 2H),6.42 (s, 1H), 6.74-6.81 (m2H), 6.82 - 6.88 (m, 1H), 6.89-6.94 (m, 1H), 7.15- 7023 (m, 2H), 7.26-7.37 (m, 2H). 2-[[1-[(2-Chlorophenyl)methyl] cyclohexyl-pyrazolyl]methoxy] methyl-propanoic acid / \ 1H NMR , 400 MHz) 5116-142 N (m, 4H), 1.54 (s, 6H), 1.57-1.81 (m, 5H), 2.36-2051 (m, 1H), 2.76- 2.91 (m, 1H), 4.56 (s,2H), 539 (s, 2H), 6.15 (s, 1H), 6.54-6.68 (m, 1H), 7.08-7.25 (m, 2H), CI 7.31-7.44 (m, 1H). 2-[[1-[(2-Chlorophenyl)methyl] cyclopentyl-pyrazoly1]methoxy] methyl-propanoic acid 16 1H NMR(CDC13, 400 MHz) 8 1.22- 1.64(m, 10H), 1.64-1.80(m, 2H), 1.82- 2.00(m, 2H), 2.80-2.92(m, 1H), 4.74(s, 2H), 5.40(s, 2H), 6.10(s, 1H), 6.58-6.62(m, 1H), 7.10-7.22(m, 2H), 738(d, 1H). 1-[[5-(4-Chloropheny1)[(2- pheny1)methy1]pyrazol y1]methoxy]cyclopropanecarboxylic acid 1H NMR (CD3OD, 400 MHz) 81.18- 132(m, 3H), 1.64-1.80(m, 1H), 4.61(s, 2H), 5.42(s, 2H), 6.52(s, 1H), .80(m, 1H), 7.20-52(m, 7H). 2-[[1-[(2-Ch10rophenyl)methyl]thiazol- 2-y1-pyrazol-3—y1]methoxy]methy1- propanoic acid 18 1H NMR (CDC13, 400 MHz) 5 138 (m, 6H), 4.48 (s, 2H), 5.61 (s, 2H), 6.55-6.65 (m, 1H), 7.03 (s, 1H), .16 (m, 1H), 7.17-7.23 (m, 1H), 7.27-7.33 (d, 1H), 7.34- 7.42 (m, 1H), 7.88-7.96 (d, 1H). +<O H 2-[[5-(4-Chloropheny1)[(2- O o fluoropheny1)methyl]pyrazol y1]methoxy]methy1-pr0panoic acid / \ 19 N N' 1H NMR (CD3OD, 400 MHz) 5 1.48 (s, C1 6H), , 2H) 538(5, 2H), 6.50(s, 1H), 6.81-6.92(m1H), 7.00-7.13(m, 2H), 7.21— 7.31 (m 1H), 7.34-7.48(m 4H) 2-[[5-(4-Chloropheny1)[(2— ch10r0pheny1)methy1]pyrazol yl]methoxy]methy1-pr0panamide 1H NMR (CD3OD 400 MHz) 5 1.46(s, 6H), 4.58(s, 2H), 540(5, 2H), 6.52(s, 1H), 6.71-6.76(m, 1H), 7.20-7.58(m 6H) 2-[[5-(4-chloropheny1)(4- pyridylmethy1)pyrazol-3 -y1] methoxy] methyl—propanoic acid 1H NMR (CD3OD 400 MHz) 5 1.52(s, 6H), 4.58(s, 2H), 556(5, 2H), 6.59(s, 1H), .52(m, 6H), 8.50 (bs, 2H) 2-[[5-(4-Chlorophenyl)(2- pyridylmethy1)pyrazoly1]meth0xy] methyl-propanoic acid 22 1H NMR (DMSO-ds, 400 MHz) 5 1.38(s, 6H), 4.40(s, 2H), 538(5, 2H), 6.41(s, 1H), .10(m, 1H), 7.20-7485(m, 6H), 8.51(bs, 1H) 2-[[5-(4-Chloropheny1)(3- pyridylmethyl)pyrazol-3 -y1] y] methyl-propanoic acid 23 1H NMR (CD3OD 400 MHz) 5 1.52(s, CI 6H), 4.58(s, 2H), 510(5, 2H), 6.55(s, 1H), 7.30-7.41(m, 3H), 7.42-7.51(m 3H), 8.19(s, 1H), 8.41(d, 1H). [(2-Ch10r0phenyl)methyl](3- thienyl)pyrazoly1]methoxy]methyl- propanoic acid. 1HNMR(CDC13): s, 6H), 438(5, 2H), 5.43(s, 2H), 6.48(s, 1H), 6.62-6.64(m, 1H), 7.17-7.31(m,3H), 7.44-7.46(m, 1H), 7.57-7.64(m, 2H). 2-[[1-[(2-Ch10rophenyl)methyl](2- thienyl)pyrazoly1]methoxy]methyl- propanoic acid. 1HNMR (CDC13): 5 1.37(s, 6H), 4.39(s, 2H), 5.47(s, 2H), 653(5, 1H), 6.59-6.61(m, 1H), 7.09-7.14(m, 2H), 7.24-7.31(m, 2H), 7.45-7.47(m, 1H), 7.62-7.64(m, 1H). 2-[[1-[(2-F1u0rophenyl)methy1](3- is0but0xypheny1)pyrazoly1]methoxy] methyl-propanoic acid 26 1HNMR(CDC13): 5 0.97 (s, 3H), 0.99( s, 3H), 1.55 (s, 6H), 2.00-2.06 (m, 1H), 3.70(d, 2H), 4.62 (s, 2H), 5.39 (s, 2H), 6.37 (s. 1H), 6.79-6.80 (m, 1H), 6.87-7.09 (M, 5H), 7.22-7.30(m, 2H) 2-[[1-[(2-Ch10rophenyl)methyl](3- oxyphenyl)pyrazoly1]methoxy] methyl—propanoic acid. 1HNMR (CDC13): 5 0.95(s, 3H)(, 0.96(s, 3H), 1.56(s, 6H), 1.97-2.03(m, 1H), 3.49(d, 2H), 4.63 (s, 2H), 5.43(s, 2H), , 1H), 6.73-6.80 (m, 2H), 6.84- 6.92(m, 2H), 7.19-7.28(m,3H), 7.33- 2016/037213 7.35(m, 1H). 2-[[1-[(2-Ch10rophenyl)methyl](3- ethoxypheny1)pyrazol-3 -y1]meth0xy]—2— methyl-propanoic acid. 28 1HNMR (CDC13): 5 1.34 (t, 3H),, 156(5, 6H), 3.86(q, 2H), 4.62(s, 2H), 5.43 (s, 2H), 6.40(s, 1H), 6.76-6.78 (m, 2H), 6.83- , 1H), 6.89-6.91(m, 1H), 7.19-7.28 (m, 3H), 7.33-7.35(m, 1H). 2-[[1-[(2-Bromophenyl)methyl](3- isopropoxypheny1)pyrazolyl]methoxy]— 2-methy1-propanoic acid. 29 1HNMR (CDC13): 5 1.21(s, 3H), 1.23(s, 3H), 4.28-4.32(m, 1H), 4.62(s, 2H), 5.39(s, 2H).6.42(s, 1H), 6.71-6.74(m, 2H), 6.82- 6.89(m, 2H), 7.11-7.15(m, 1H), 7.22- 7.27(m, 2H), 7.51-7.54(m, 1H). [(2-Bromophenyl)methyl](3- methoxyphenyl)-1H-pyrazol yl]methoxy]methy1pr0panoic acid 1HNMR (CDC13): 5 1.56(s, 6H), 3.65(s, 3H), 4.62(s, 2H), 5.39(s, 2H), 6.41(s, 1H), 6.73-6.76(m 2H), 6.84-6.92(m, 2H), 7.15(t, 1H), 7.13-7.29(m, 2H), 7.52- 7.54(m, 1H). 2-[[1-[(2-1sopropylphenyl)methyl](3- methoxyphenyl)pyrazoly1]meth0xy]—2- —propanoic acid. 1HNMR (CDC13): 51.13 (s, 3H), 1.15(s, 31 3H), 1.55 (s 6H), 2.94—2.97(m, 1H), 3.62(s, 3H),4.63(s, 2H), 542(5, 2H), 6.39(s, 1H),6.65-6.67(m,1H), 6.75-6.76(m, 1H), .91(m, 2H), 7.07-7.11(m, 1H),7.21—7.28(m, 3H) 2-[[5-(3-Methoxyphenyl)(0- ethy1)pyrazolyl]methoxy]—2- methyl-propanoic acid. 1HNMR (CDC13): 5 1.55 (s, 6H), 2.18 (s, 3H), 3.64( s, 3H), 4.62 9s, 2H), , 2H), , 1H), 6.69-6.31(m, 1H),6.77- 678(m, 1H), 6.86-6.92 (m, 2H), 7.10—7.15 (m, 3H), 7.25-7.29 (m, 1H). 2-[[1-[(2-Ch10rophenyl)methyl][3- (cyc10pr0py1methoxy)phenyl]pyrazol yl]methoxy]methy1—propan0ic acid. 1HNMR (CDC13): 5 .29(m, 2H), 33 0.58—0.63(m, 2H), 14.16—1.20(m, 1H), 1.55(s, 6H), 5.58(d, 2H), 4.63(s, 2H), .42(s, 2H), 6.40(s, 1H), 6.374-6.78(m, 2H), 6.84—6.93(m, 2H), 7.18—7.28(m, 3H), 7.33-7.35(m, 1H). 2-[[1-[(2-Ch10rophenyl)methyl][3- (trifluoromethoxy)phenyl]pyrazol yl]methoxy] methy1—pr0pan0ic acid. 34 1HNMR ): 51.56(6H), 4.63(s, 2H), .41(s, 2H), 6.46(s, 1H), 6.77-6.79(m, 1H), 7.12-7.25(m, 5H), 7.32-7.35(m, 1H), 7.38- 7.42 (m, 1H). 2-[[1—[(2-Ch10rophenyl)rnethyl](3— is0pr0p0xypheny1)pyrazol-3 -yl]meth0xy]— 2-methy1-propan0ic acid. \l/0 1HNMR (CDC13): 5 1.22(s, 3H)(, 1.23(s, 3H), 1.55(s, 6H), 4.30—4.33(m, 1H), 4.62(s, 2H), 5.43(s, 2H), 6.41(s, 1H), 6.75- 6.90(4H), 7.19—7.35(m, 4H). 2-[[5-(3-Methoxyphenyl)[(2— methoxyphenyl)methyl] pyrazol-S- hoxy] methy1—pr0pan0ic acid. 36 1HNMR ): 5 1.55(s. 6H), 3.70(s, 3H), 3.73(s, 3H), 4.62(s, 2H), , 2H), 6.35(s, 1H), 6.77-6.392(m, 6H), 7.22- 7.29(m, 2H). [(2-Ch10rophenyl)methyl][3- (cyclobutoxy)phenyl]pyrazol yl]methoxy]methy1-propanoic acid. 1HNMR (CDC13): 5 149-161 (m, 7H), m1.75-1.82(m 1H), 2.01-2.11(m 2H), 2.17-2.24(m 2H), 4.37—4.45(m1H), 4.62(s, 2H), 5.42(s, 2H), 639(5, 1H), 6.64(s, 1H), 6.75-6.86( m, 3H), 7.19—7.35(m 4H). 2-[[1-[[2-(Dimethy1amin0)phenyl]methyl]- -(3 -methoxypheny1)pyrazol-3— yl]methoxy]methy1—propan0ic acid. 38 ’ 1HNMR (CDC13): 5 1.56(s, 6H), 2.60(s, 6H), 6.64(s, 3H), 463(3, 2H), 5.44(s, 2H). 630(s, 1H), 6.71-7.11(m 6H), 7.20— 7.25(m, 2H). 2-[[1-[(2-Chlorophenyl)methyl][3- (cyc1opropoxy)pheny1]pyrazol hoxy]methy1-pr0panoic acid. 39 1HNMR (CDC13): 5 0.55-0.68(m 4H), 1.55(s, 6H), 3.50-3.54(m 1H), 4.63(s, 2H), .44 (s, 2H), 6.42 (s, 1H), 6.76-7.02( m, 4H), 7.17-7.35 (m, 4H). \7 c :0“ 2-[[1-[(2-Ch10r0phenyl)methyl][3- o o (morpholinomethy1)pheny1]pyrazol y1]methoxy]methy1—propan0ic acid. 40 (\N N 0Q kg 1HNMR (CD3OD): 5 1.50 (s, 6H), 3.15— 3.23 (bs, 4H), 3.60-3.81 (bs, 2H), 3.85- 4.16(bs, 2H), 4.35(s, 2H), 4.57(s, 2H), .45(s, 2H), 6.60 (s, 1H), 6.75 (d, 1H), 7.20-7.55 (m, 7H). 1-[[1-[(2-Ch10rophenyl)methyl](3- yphenyl)pyrazol-3 - y1]methoxy]cyclobutanecarboxylic acid. 1HNMR (CDC13): 5 1.78-1.85 (m 1H), 41 .04 (m, 2H), 2.18-2.25 (m, 1H), 3.09-3.14(m, 1H), 3.66(s, 3H), 4.27-4.32 (m, 1H), 4.55-4.65 (dd, 2H), 5.43 (s, 2H), 6.44 (S> 1H), 6.73-6,91(m, 4H), 7.17-7.34 (m 4). 2-[[1-[(2-Chlorophenyl)methyl][3- (cyc10buty1meth0xy)phenyl]pyrazol yl]methoxy]methy1-pr0panoic acid. 1HNMR (CDC13): 5 1.55(s, 6H),1.75- 1.82(m, 2H),1.85-1.98(m, 2H), 2.06— 2.14(m, 2H), 264-270(m, 1H), 3.71(d, 2H), 4.63(s, 2H), 5.43(s, 2H), , 1H), 6.75-6.92(m, 4H), 7.20-7.36(m, 4). 2-[[1-[(2-Chlorophenyl)methyl][3- (2,2,2-trifluoroethoxy)phenyl]pyrazol yl]methoxy] methy1-propan0ic acid. 43 1HNMR (CDC13): 5 1.55(s, 6H), 4.16(q, 2H), 4.63(s, 2H), 5.42(s, 2H), 6.43(s, 1H), 6.77-6.81(m, 2H), 6.96-6.98(m, 2H), 7.19- 7.36(m, 4H). 2-[[1-[(2-Ch10rophenyl)methyl][3- (cyc10penty1methoxy)phenyl]pyrazol yl]methoxy]methy1-propanoic acid. 1HNMR (CDC13): 5 .29(m, 2H), 1.55-1.61(m, 10H), 1.76-1.79(m, 2H), 2.24-2.31(m, 1H), 3.59(d, 2H), , 2H), 5.43(s, 2H), 641(5, 1H), 6.73-6.91(m, 4H), 7.19-7.35(m, 4H). 2-[[1-[(2-Ch10rophenyl)methyl][3- (tetrahydropyran ylmethoxy)pheny1]pyrazolyl]methoxy]— 2-methy1-propanoic acid. 1HNMR (CDC13): 5 .41(m, 55(s, 6H), 1.66-1.69(m, 2H), 1.97- 1.99(m, 1H), 3.38—3.46m, 2H), 3.56(d, 2H), 3.98-4.01(m, 2H), 4.62(s, 2H), 5.42(s, 2H), 6.42(s, 1H), 6.71(s, 1H), 6.77-6.95(m, 3H), 7.19-7.35(m, 4H). 2-[[1-[(2-Ch10r0phenyl)methyl](3- morpholinopheny1)pyrazolyl]methoxy] - 2-methy1-propanoic acid. 46 1HNMR (CDC13): 5 1.55(s, 6H), 2.96(t, 4H), 3.76(t, 4H), 4.62(s, 2H), 5.41(s, 2H), 6.41(s, 1H), 6.68(s, 1H), 6.78-6.80(m, 2H), .91(m, 1H), 7.19-7435(m, 4H). 2-([1-[(0-Chlorophenyl)methyl](1,3- thiazoly1)-1H-pyrazoly1]methoxy) methylpropionic acid 47 1HNMR(CDC13): 5 1.56(s, 6H), 4463(5, 2H), 5.84(s, 2H), 6.62-6.67(m, 2H), 7.10— 7.19(m 2H), 7.33-7.35(m, 1H), , 1H), 8.83(d, 1H). 2-([1 -[(0-Ch1orophenyl)methyl](m- cyanophenyl)— 1H-pyrazol-3 -y1]methoxy)- 2-methy1propionic acid 48 1HNMR(CDC13): 5 1.56(s, 6H), 4.62(s, 2H), 5.39(s, 2H), 6.46(s, 1H), 6.82-6.84(m, 1H), 7.18-7.24(m, 2H), 7.33-7.35(m 1H), 7.46-7.55(m, 3H), 7.65-7.68(m, 1H). 2-([1-[(0-Chlorophenyl)methyl]—5-(1,3- thiazol-S-y1)-1H—pyrazolyl]methoxy) methylpropionic acid 49 CDC13): 5 1.56(s, 6H), 4.62(s, 2H), 5.50(s, 2H), .6(m, 2H), 7.14— 7.24(m, 2H), 7.36-7.38(m, 1H), 7.76(s, 1H), 8.84(s, 1H). 2-([1-[(0-Chlorophenyl)methyl][m- (dimethylarnino)phenyl]— 1H-pyrazol yl]methoxy)methylpropionic acid MS: Calculated: 427.92; Found: 4289 [M+H].

Example 51: 2-([1-[(2-Chlorophenyl)methyl][3-(pr0panyl)phenyl]-1H-pyrazol yl]methoxy)methylpropanoic acid. (i) 1-[3—(Pr0pcm—2—yl)phenyl]ethan0ne: Into a 500-mL round-bottom flask purged and maintained with an inert here ofN2 was placed a solution of 1-bromo (propanyl)benzene (5.0 g, 25.11 mrnol, 1.00 equiv) in THF (250 mL). This was followed by the on of n-BuLi (20 mL, 2.00 equiv) dropwise with stirring at -60 °C. The mixture was stirred at -60 °C for 30 min. To this was added oxy-N—methylacetarnide (3.9 g, 37.82 mmol, 1.50 equiv) dropwise with stirring at -30 0C. The resulting on was stirred for 3 h at -30 0C in a liquid N2 bath. The reaction was then quenched by the addition of 20 mL of water. The resulting on was d with 200 mL of EtOAc, washed with 2X100 mL of brine, dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1: 10). This resulted in 2.7 g (66%) of the title product as colorless oil. (ii) 2, 4-Dl'0x0[3-(pr0pany0phenyl]butan0ate: Into a 100-mL round-bottom flask, MeONa (9.25 mL of 25% solution in MeOH, 3.00 equiv, 5.4%) was added to a solution of 1-[3-(propanyl)phenyl]ethan-l-one (2.7 g, 16.64 mmol, 1.00 equiv) in MeOH (30 mL).

This was ed by the addition of dimethyl oxalate (1.97 g, 16.68 mmol, 2.00 equiv), in portions at room temperature. The resulting solution was stirred for 16 h at room temperature.

The reaction was then quenched by the addition of 200 mL of water/ice. The pH value of the solution was adjusted to 3-4 with conc HCl. The resulting solution was extracted with 3X100 mL of EtOAc and the organic layers were combined, washed with 2x100 mL of brine, dried, and evaporated. The solid was dried in an oven under reduced pressure. This resulted in 4.0 g (97%) of the title product as yellow oil. (iii) Methyl 1-[(2-chlor0pheny0methyl]—5—[3-(pr0pan-2—y0phenyl]-1H—pyrazole- 3-carb0xylaz‘e: Into a 50-mL bottom flask was placed a solution of methyl 2,4-dioxo-4— [3-(propanyl)phenyl]butanoate (1.0 g, 4.03 mmol, 1.00 equiv) and [(2- chlorophenyl)methyl]hydrazine dihydrochloride (1.38 g, 6.01 mmol, 1.50 equiv) in AcOH (20 mL). The resulting solution was stirred for 2 h at 100 °C in an oil bath. The resulting mixture was concentrated under vacuum, diluted with 200 mL of EtOAc, washed with 2x100 mL of sat NaHCO3, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1 :5). This resulted in 1.05 g (71%) of the title product as a yellow solid. (iv) 2—([1-[(2—Chlorophenyl)methyZ][3-(propan-Z—ybphenyl}IH-pyrazol-S- yljmez‘hoxy)-2—methylpr0panoic acid was prepared analogously as described in Steps ii-iv of Example 1. This resulted in 70 mg as a white solid. 1H-NMR (300 MHz, MeOD): 8 1.12 (6 H, d), 1.53 (6 H, s), 2.83 (1 H, p), 4.60 (2 H, s), 5.40 (2 H, s), 6.54 (1 H, s), 6.72 — 6.81 (1 H, m), 7.05 — 7.45 (7 H, m). es 52-59 were prepared analogously as bed in Example 51. [(2-chlorophenyl)methyl][3- (methoxymethyl)phenyl]—1H-pyrazol yl]methoxy)methylpropanoic acid 1H-NMR (300 MHz, MeOD): 5 1.52 (6 H, s), 4.42 (2 H, s), 4.59 (2 H, s), 5.42 (2 H, s), 6.56 (1 H, s), 6.70 — 6.80 (1 H, m), 7.17 — 7.33 (4 H, m), 7.32 — 7.45 (3 H, m). 2- [ [1 -benzy1-5 -(3-methoxypheny1)-1H- HOH pyrazoly1]methoxy]methy1propanoic acid 0 O 53 /o / \ [0247] 1H-NMR (300 MHz, MeOD) 6 1.51 (6 N’N H, s), 3.68 (3 H, s), 4.57 (2 H, s), 5.35 (2 H, s), 6.48 (1 H, s), 6.84 (1 H, dd), 6.89 — 7.06 (4 H, m), 7.17 — 7.38 (4 H, m). 2-({1-[(o-Chloropheny1)methy1](m— methoxypheny1)—4-methyl-1H-pyrazol hoxy)—2-methylpropionic acid 1H-NMR;(300 MHz, MeOD) 5 1.53 (6 H, s), 2.09 (3 H, s), 3.67 (3 H, s), 4.60 (2 H, s), 5.31 (2 H, s), 6.67 — 6.86 (3 H, m), 6.97 (1 H, ddd), 7.17 — 7.40 (4 H, m). 2- [ [5 -(3-meth0xyphenyl)—1-pheny1-1H- pyrazol-3 -y1]methoxy]-2—methy1pr0panoic acid 55 [0248] 1H—NMR (300 MHz, MeOD) 5 1.53 (6 H, s), 3.64 (3 H, s), 4.61 (2 H, s), 6.63 — 6.77 (2 H, m), 6.77 — 6.93 (2 H, m), 7.16 — 7.36 (3 H, m), 7.40 (3 H, dddd). 2-[[5-(3-methoxypheny1)—1-(pyridiny1)— 1H-pyrazoly1]methoxy] methylpropanoic acid LC-MS (ES, m/Z): 367 1H-NMR (400 MHz, MeOD) 5 1.54 (6 H, s), 3.69 (3 H, s), 4.65 (2 H, s), 6.70 (1 H, s), 6.76 — 6.78 (2 H, m), 6.89(1 H, ddd), 7.20 — 7.25 (1H, d), 7.41 - 7.45 (2H, m), 7.91 (1 H, dt), 8.41 (1 H, t). 2- [ [1 -(2-chloropheny1)(3-methoxypheny1)- 1H-pyrazoly1]methoxy] methylpropanoic acid LC-MS (ES, m/Z): 401 1H-NMR (400 MHz, MeOD) 5 1.55 (6 H, s), 3.64 (3 H, s), 4.63 (2 H, s), 6.73 (2 H, d), 6.86 (2 H, dd), 7.20 (1 H, dd), 7.42 — 7.60 (4 H, 2- [ [1 -(3-chlorophenyl)(3-methoxyphenyl)- 1H-pyrazolyl]methoxy] methylpropanoic acid 1H-NMR (400 MHz, MeOD) 5 1.54 (6 H, s), 3.71 (3 H, s), 4.62 (2 H, s), 6.68 (1 H, s), 6.77 — 6.87 (2 H, m), 6.94 (1 H, ddd), 7.19 (1 H, dt), 7.27 (1 H, t), 7.32 — 7.44 (3 H, m). 2- [ [1 lorophenyl)—5-(3-methoxyphenyl)- 1H-pyrazolyl]methoxy] methylpropanoic acid LC-MS (ES, m/z): 401 1H-NMR (400 MHz, MeOD) 5 1.54 (6 H, s), 3.71 (3 H, s), 4.62 (2 H, s), 6.67 (1 H, s), 6.75 — 6.85 (2 H, m), 6.92 (1 H, ddd), 7.21 — 7.32 (3 H, m), 7.37 — 7.46 (2 H, m). e 60: 2-([1-Benzyl[3-(2-methylpr0poxy)phenyl]-1H-pyrazolyl]methoxy) methylpropanoic acid.

: OH /k/ 0 0 O / \N (i) 1-[3-(2-Methylpr0p0xy)phenyljethan0ne: Into a 500-mL round-bottom flask was placed a solution of 1-(3—hydroxyphenyl)ethanone (20 g, 146.90 mmol, 1.00 equiv), K3PO4 (62 g, 292.08 mmol, 2.00 equiv) and 1-bromomethylpropane (40 g, 291.93 mmol, 2.00 equiv) in DMSO (240 mL). The resulting solution was stirred for 16 h at 60 0C.

The resulting solution was extracted with 2x500 mL of EtOAc, and the organic layers were combined and dried over anhydrous NazSO4. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1 :5). This resulted in 21.24 g (75%) of the title product as a yellow liquid. (ii) Benzyl[3-(2-methylpr0p0xy)phenyfj-IH-pyrazol-S—yljmethoxy)-2— methylpropanoic acid was obtained analogously to Example 67. This resulted in 103.1 mg as a white solid. 1H-NMR (400 MHz, MeOD) 5 0.97 (6 H, d), 1.53 (6 H, s), 1.97 (1 H, dp), 3.48 (2 H, d), 3.78 (3 H, s), 4.58 (2 H, s), 5.31 (2 H, s), 6.52 (1 H, s), 6.67 — 6.74 (1 H, m), 6.76 — 6.82 (1 H, m), 6.85 — 7.00 (4 H, m), 7.22 — 7.33 (2 H, m).

Examples 61-63 were prepared analogously as described in Example 60. 2-([l -[(2-methoxyphenyl)methyl] [3 -(2- methylpropoxy)phenyl]—lH-pyrazol-S- yl]methoxy)methylpr0pan0ic acid LC-MS (ES, m/z): 453 61 1H-NMR (400 MHz, MeOD) 5 0.97 (6 H, d), 1.53 (6 H, s), 1.97 (1 H, dp), 3.48 (2 H, d), 3.78 (3 H, s), 4.58 (2 H, s), 5.31 (2 H, s), 6.52 (1 H, s), 6.67 — 6.74 (1 H, m), 6.76 — 6.82 (1 H, m), 6.85 — 7.00 (4 H, m), 7.22 — 7.33 (2 H, 2-([1-[(3-methoxyphenyl)methyl][3-(2- methylpropoxy)phenyl]—1H-pyrazol yl]methoxy)methylpr0pan0ic acid LC-MS (ES, m/z): 453 62 1H-NMR (400 MHz, MeOD) 5 0.99 (6 H, d), 1.53 (6 H, s), 1.99 (1 H, dq), 3.55 (2 H, d), 3.73 (3 H, s), 4.59 (2 H, s), 5.33 (2 H, s), 6.50 (1 H, s), 6.56 — 6.65 (2 H, m), 6.78 — 6.86 (2 H, m), 6.92 — 7.00 (2 H, m), 7.22 (1 H, t), 7.33 (1 H, t). 2-([l -[(4-meth0xyphenyl)methyl] [3 -(2- methylpropoxy)phenyl]-lH-pyrazol yl]methoxy)methylpropanoic acid LC-MS (ES, m/z): 453 1H-NMR (400 MHz, MeOD) 5 1.00 (6 H, d), 1.53 (6 H, s), 2.01 (1 H, dp), 3.57 (2 H, d), 3.77 (3 H, s), 4.58 (2 H, s), 5.29 (2 H, s), 6.47 (1 H, s), 6.78 — 6.90 (3 H, m), 6.92 — 7.01 (4 H, m), 7.29 — 7.39 (1 H, m). e 64: 2-([1-[(2-Chlor0phenyl)methyl](5-meth0xythiophen-2—yl)—1H-pyrazol-3— yl]methoxy)methylpropanoic acid. (i) 1-(5—Meth0xythi0phenyl)ethan-I-one: Into a 25-mL sealed tube was placed 2-methoxythiophene (11 g, 96.35 mmol, 1.00 equiv), MeOH (60 mL), CszCO3 (22 g, 1.20 equiv), and Brettphos Pd G3 (550 mg). The final reaction mixture was irradiated with ave radiation for 1 h at 100 0C. The resulting mixture was concentrated under vacuum. The resulting solution was extracted with 3x100 mL of EtOAc, and the organic layers were combined, dried over ous MgSO4, and concentrated under vacuum. The e was applied onto a silica gel column with EtOAc/petroleum ether (1/50). This resulted in 5 g (33%) of the title product as ayellow solid. (ii) 2-([1-[(2-Chlorophenyl)methyl]-5—(5-methaxythiophen-Z—yl)-1H-pyrazol yljmethoxy)me2‘hylpr0pan0ic acid was prepared analogously as described in Steps ii-iv of Example 51. This resulted in 39.2 mg as a white solid. 1H-NMR (300 MHz, MeOD): 5 1.51 (6 H, s), 3.86 (3 H, s), 4.54 (2 H, s), 5.50 (2 H, s), 6.19 (1 H, d), 6.51 (1 H, s), 6.55 — 6.66 (2 H, m), 7.25 (2 H, dtd), 7.43 (1 H, dd).

Example 65: 2-([1-[(2-Chlor0phenyl)methyl]-5—(4-meth0xythiophen-2—yl)—1H-pyrazol-3— yl]methoxy)methylpropanoic acid. %_<OH O O 3 /:N \/ N ClK/[> (i) 1-(4-Meth0xythi0phenyl)ethan-I—one: Into a 50-mL round—bottom flask purged and ined with an inert atmosphere ofN2 was placed a solution of 1-(4- bromothiophenyl)ethanone (3.0 g, 14.63 mmol, 1.00 equiv) in MeOH (25 mL). This 2016/037213 was followed by the addition ofNaOMe (5.4 mL, 2.00 equiv, 5.4M) at room temperature. To this was added CuBr (627 mg, 4.38 mmol, 0.30 equiv) at room temperature. The ing solution was stirred for 16 h at 100 0C in an oil bath, then diluted with 100 mL of EtOAc, washed with 2x100 mL of brine, dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1 :20). This resulted in 700 mg (31%) of the title product as a yellow oil. (ii) [(2-Chlorophenyl)methyl]-5—(4-methoxythiophen-Z—yl)-1H—pyrazol yljmez‘hoxy)-2—methylpr0panoic acid was prepared analogously as described in Steps ii-iv of Example 51. This resulted in 61 mg as a white solid. 1H-NMR (300 MHz, MeOD): 5 1.51 (6 H, s), 3.76 (3 H, s), 4.56 (2 H, s), 5.54 (2 H, s), 6.51 (1H, d), 6.56 — 6.69 (3 H, m), 7.26 (2 H, dtd), 7.44 (1 H, dd).

Example 66: 2-([1-[(2-chlorophenyl)methyl]-5—(5-methoxythiophen-S-yl)—1H-pyrazol yl]methoxy)-2—methylpropanoic acid was prepared analogously as described in Example 1H-NMR (400 MHz, MeOD) 5 1.53 (6 H, s), 3.85 (3 H, s), 4.57 (2 H, s), 5.52 (2 H, s), 6.26 (1 H, d), 6.52 — 6.59 (2 H, m), 6.64 — 6.71 (1 H, m), 7.28 (2 H, dtd), 7.45 (1 H, dd). e 67: 2-([1- [(0-Chlorophenyl)methyl]-5—(m-meth0xyphenyl)—1H-pyrazol-3— yl)methoxy)-2—ethylbutyric acid was prepared analogously as described in Example 1, except that in place of Step iii, the following procedure was followed: (i) Methyl 2—ethyl—2—hydr0xybutanoate: Into a 250-mL bottom flask was placed a solution of 2-ethylhydroxybutanoic acid (2.0 g, 15.13 mmol, 1.00 equiv) in MeOH (100 mL). This was followed by the addition of ic acid (3 mL) dropwise with stirring at room temperature. The resulting solution was heated to reflux for 16 h in an oil bath. The resulting mixture was concentrated under vacuum, diluted with 200 mL of EtOAc, washed with 2X100 mL of sat NaHCO3, dried over anhydrous Na2SO4 and concentrated under . This resulted in 800 mg (36%) of the title t as a colorless oil. (ii) 3-(Br0m0methyU[(2—chlor0pheny0methyl](3-meth0xyphenyU-1H- pyrazole: Into a 100-mL round-bottom flask was placed a solution of [1-[(2- chlorophenyl)methyl](3-methoxyphenyl)-1H-pyrazolyl]methanol (600 mg, 1.82 mmol, 1.00 equiv) in DCM (30 mL). This was followed by the addition of CBr4 (900 mg, 1.50 equiv) at 0 °C over 1 min. To this was added PPh3 (720 mg, 2.75 mmol, 1.50 equiv) in several batches at 0 0C over 5 min. The resulting solution was stirred for 16 h at 25 °C in an oil bath. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1:11).

The collected fractions were combined and concentrated under vacuum. This resulted in 550 mg (77%) of the title product as a yellow oil. [025 8] (iii) Methyl 2-([1-[(2-ch10r0phenyl)methylj(3-methoxyphenyl)-1H—pyrazol hoxy)-2—ethylbutan0ate: Into a 40—mL vial was placed a solution of methyl 2-ethy1-2— hydroxybutanoate (371 mg, 2.54 mmol, 2.00 equiv) in DMF/THF (7/7 mL). This was followed by the addition ofNaH (100 mg, 4.17 mmol, 2.00 equiv) at 0 0C in 30 min. To this was added NaI (140 mg) and 3-(bromomethyl)[(2-chlorophenyl)methyl](3- methoxyphenyl)-1H-pyrazole (500 mg, 1.28 mmol, 1.00 . The resulting solution was stirred for 16 h at room temperature. The residue was applied onto a Prep-TLC with EtOAc/petroleum ether (1:10). The collected fractions were combined and concentrated under vacuum. This resulted in 210 mg (38%) of the title product as a white liquid.

LiOH treatment as in Step iv of Example 1 ed in 210 mg of the title compound as a white liquid. 1H-NMR (400 MHz, MeOD): 5 (0.91 (6 H, t), 1.87 (4 H, q), 3.68 (3 H, s), 4.52 (2 H, s), 5.43 (2 H, s), 6.67 (1 H, s), 6.72 — 6.86 (2 H, m), 6.88 — 7.00 (2 H, m), 7.21 — 7.36 (3 H, m), 7.37 — 7.48 (1 H, m).

Example 68: 2-([1-[(2-Chlorophenyl)methyl](3-meth0xyphenyl)—1H-pyrazol-3— hoxy)methylbutan0ic acid was prepared analogously as described in e 64. 1H-NMR (400 MHz, MeOD) 5 0.97 (3 H, t), 1.51 (3 H, s), 1.89 (2 H, qd), 3.68 (3 H, s), 4.59 (2 H, s), 5.44 (2 H, s), 6.56 (1 H, s), 6.71 — 6.79 (1 H, m), 6.83 (1 H, dd), 6.89 — 7.01 (2 H, m), 7.22 — 7.36 (3 H, m), 7.37 — 7.45 (1 H, m).

Example 69: 2-([1-[(2-Chlorophenyl)methyl]-5—[3-(2-methylpropanamido)phenyl]-1H- pyrazolyl]methoxy)methylpr0panoic acid. +<OH O O / \N o N’ (i) Methyl 4-(3-nitr0phenyU-2,4-dl'0x0butan0ate: Into a 1000-mL 3-necked round- bottom flask, MeONa (90 mL, 4.00 equiv), and dimethyl oxalate (18.6 g, 157.51 mmol, 1.30 equiv) were added stepwise to a on of 1-(3-nitrophenyl)ethanone (20 g, 121.10 mmol, 1.00 equiv) in MeOH (700 mL). The resulting solution was stirred overnight at room temperature. The resulting solution was poured into 500 mL of H20/ice. The pH value of the solution was adjusted to 3-5 with HCl (12 mol/L). The resulting solution was extracted with 2x1000 mL of EtOAc and the organic layers were combined, washed with 2x1000 mL of 2016/037213 brine, dried over anhydrous Na2$04 and concentrated under vacuum. This resulted in 18 g (59%) of the title product as a yellow solid. (ii) Methyl 'tr0phenyl)-IH-pyrazole-S-carboxylate: Into a 500-mL round- bottom flask was placed a solution of methyl 4-(3-nitrophenyl)-2,4-dioxobutanoate (15 g, 59.72 mmol, 1.00 equiv) and H2NNH2 hydrate (3.9 mL, 1.20 equiv) in AcOH (200 mL). The resulting on was stirred for 3 h at 120 °C in an oil bath. The reaction mixture was cooled to room temperature. The solids were collected by filtration. This ed in 9.5 g (64%) of the title product as a yellow solid. (iii) Methyl 1-[(2-chlor0phenyl)methyl](3-nizr0phenyl) -1H—pyrazole carboxylate: Into a 25-mL 3-necked round—bottom flask purged and maintained with an inert atmosphere of N2, was placed a solution of methyl 5-(3-nitrophenyl)-1H—pyrazole carboxylate (9.0 g, 36.41 mmol, 1.00 equiv) in toluene (170 mL). This was followed by the addition of NaH (2.92 g, 73.00 mmol, 2.00 equiv, 60%), in portions at room temperature. The reaction was stirred at It for 30 mins. To this was added a solution of 1-(bromomethyl) chlorobenzene (11.2 g, 54.51 mmol, 1.50 equiv) in toluene (30 mL) dropwise with stirring at 60 0C. The resulting solution was stirred for 5 h at 110 0C in an oil bath. The reaction mixture was cooled to room temperature. The reaction was then quenched by the addition of 200 mL of sat NH4Cl. The resulting solution was diluted with 300 mL of EtOAc. The resulting solution was extracted with 2x300 mL of EtOAc and the organic layers were combined, washed with 3x300 mL of brine, dried over Na2$O4 and concentrated under vacuum. The residue was applied onto a silica gel column with PEzEtOAc (3: 1). This resulted in 4.0 g (30%) of the title t as a white solid. (iv) Methyl 2-([1-[(2-chl0r0phenyUmethylj(3-m'trophenyD-JH-pyrazol-S- yljmez‘hoxy)-2—methylpr0pan0ate was prepared analogously as described in Steps ii-iii of Example 1.

(V) Methyl 2-[[5-(3-amin0phenyl)[(2-chl0r0phenyl)methyl]—1H-pyrazol yljmethoxyj-Z-methylpropanoate: Into a 25-mL round-bottom flask was placed a on of methyl 2-([1-[(2-chlorophenyl)methyl](3 -nitrophenyl)-1H-pyrazolyl]methoxy) methylpropanoate (400 mg, 0.90 mmol, 1.00 equiv) in AcOH/HzO (10/1 mL). This was ed by the addition of Zn (400 mg, 6.15 mmol), in ns at room temperature. The resulting mixture was stirred for 2 h at room temperature. The solids were removed by filtration. The pH value of the solution was adjusted to 7-8 with sat . The resulting solution was extracted with mL of EtOAc, and the organic layers were combined, washed with 2x200 mL of brine, dried over anhydrous Na2S04 and concentrated under vacuum. The residue was purified by Prep-TLC with OH (30:1). This resulted in 230 mg (62%) of the title product as a yellow oil. (vi) Methyl 2-([1-[(2—cklor0phenyl)metkylj[3—(2—metkylpropanamidOMhenylj— 1H-pyrazolyljmeth0xy)methylpr0pan0ate: Into a 40-mL flask was placed a on of methyl 2-[[5-(3-aminophenyl)[(2-chloropheny1)methy1]-1H-pyrazol-S-yl]methoxy] methylpropanoate (200 mg, 0.48 mmol, 1.00 equiv), HATU (276 mg, 0.73 mmol, 1.50 equiv), 2-methy1propanoic acid (130 mg, 1.48 mmol, 3.00 equiv) and DIEA (187 mg, 1.45 mmol, 3.00 equiv) in DMF (20 mL). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 200 mL of EtOAc, washed with 2x100 mL of brine, dried over anhydrous NazSO4 and concentrated under vacuum. The residue was purified by Prep-TLC with DCM/MeOH (30:1). This resulted in 155 mg (66%) of the title product as a yellow solid, (viii) 2—([1-[(2-Ch10r0pheny0methy]]-5—[3-(2—methylpropanamid0)phenyl]—1H— pyrazol-S-yljmethoxy)methylpr0panoic acid was prepared analogously as described in Step iv of Example 1. This ed in 70 mg (48%) as a white solid. 1H-NMR (300 MHz, DMSO) : 5 1.09 (6 H, d), 1.39 (6 H, s), 2.57 (1 H, p), 5.39 (2 H, s), 6.40 (1 H, s), 6.69 — 6.79 (1 H, m), 7.00 (1 H, dt), 7.21 — 7.48 (4 H, m), 7153 — 7.63 (1 H, m), 7.78 (1 H, t), 9.93 (1 H, Example 70: 2-([1-[(2-chlorophenyl)methyl]-5—(3—methanesulfonylphenyl)—1H-pyrazol-3— yl]methoxy)methy1propanoic acid. (i) Methyl 2—([1-[(2-chlor0phenyl)methylj[3-(methylsulfanybphenylj-1H- pyrazol-S-yljmethoxy)methylpr0pan0ate: Into a 30-mL flask purged and ined with an inert atmosphere of N2, was placed a on of methyl 2—[[5-(3—aminophenyl)[(2- chlorophenyl)methyl]-1H-pyrazolyl]methoxy]methylpropanoate (700 mg, 1.69 mmol, 1.00 equiv—-prepared analogously as described in Example 69) in MeCN (10 mL). This was followed by the addition of dimethyl disulfide (319 mg, 3.39 mmol, 2.00 . The resulting mixture was heated 60 0C for 1h. To this was added tert-butylnitrite (350 mg, 3.40 mmol, 2.00 equiv) dropwise with stirring at room temperature. The resulting solution was stirred for 3 h at 60 °C in an oil bath, then diluted with 200 mL of EtOAc, washed with 2x100 mL of brine, dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto Prep-TLC with EtOAc/petroleum ether (1:2). This resulted in 300 mg (40%) of the title product as a yellow oil. (ii) Methyl 2-([I-[(2-ch10r0phenyl)methyU(3—methanesulfonylphenyU—IH- pyrazol-S—yljmethoxy)-2—methylpr0pan0ate: Into a 25-mL round-bottom flask was placed a solution of methyl 2-([1-[(2-chlorophenyl)methyl][3-(methylsulfanyl)phenyl]-1H-pyrazol- 3-yl]methoxy)methylpropanoate (300 mg, 0.67 mmol, 1.00 equiv) in zO (10/5 mL). This was followed by the addition of dipotassium O- [(sulfonatoperoxy)sulfonyl]oxidanidolate (233 mg, 1.53 mmol, 1.00 equiv), in portions at room temperature. The resulting solution was d for 2 h at room temperature, then diluted with 200 mL of EtOAc, washed with 2x100 mL of brine, dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto Prep-TLC with EtOAc/petroleum ether (1:3). This ed in 180 mg (58%) of the title product as a yellow solid. (iii) 2—([1-[(2-Ch10r0phenyl)methylj(3-methanesulfonylphenyl)-1H—pyrazol yljmez‘hoxy)mez‘hylpr0pan0ic acid was prepared analogously as described in Step iv of Example 1. This resulted in 30 mg (17%) as a white solid. 1H-NMR (400 MHz, MeOD) :5 1.54 (6 H, s), 3.10 (3 H, s), 4.61 (2 H, s), 5.48 (2 H, s), 6.67 (1 H, s), 6.82 (1 H, dd), 7.21 — 7.33 (2 H, m), 7.35 — 7.42 (1 H, m), 7.64 — 7.74 (2 H, m), 7.90 (1 H, q), 7.96 — 8.03 (1 H, m).

Example 71: 2-([1-[(2-chlor0phenyl)methyl](3-methanesulfonamidophenyl)-1H- pyrazolyl]methoxy)methylpr0panoic acid. (1) Methyl 2-([1-[(2-chlor0phenyl)methylj(3-methanesulfonamidophenyl)-1H— l—3—yZ]methoxy)methylpr0pan0ate: Into a 25-mL round-bottom flask was placed a solution of methyl 2-[[5-(3-aminopheny1)—1-[(2-chlorophenyl)methyl]-1H-pyrazol yl]methoxy]methy1propanoate (200 mg, 0.48 mmol, 1.00 equiv——prepared analogously as described in Example 69), pyridine (75 mg, 0.95 mmol, 2.00 equiv), and 4-dimethylamino- pyridine (6 mg, 0.05 mmol, 0.10 equiv) in DCM (10 mL). This was followed by the addition of methanesulfonyl de (83 mg, 0.72 mmol, 1.50 equiv) dropwise with stirring at 0 0C, The resulting solution was stirred overnight at room temperature, then diluted with 100 mL of DCM, washed with 2X100 mL of brine, dried over anhydrous NazSO4 and trated under vacuum. The residue was applied onto Prep-TLC with EtOAc/petroleum ether (1 :4). This resulted in 100 mg (42%) of the title product as a yellow oil. (ii) 2-([1-[(2—C}zZorophenyl)methylj(3—methanesulfonamidophenylj-JH— pyrazol-S-yljmethoxy)methylpr0panoic acid was ed analogously as described in Step iv of Example 1. This resulted in 30.2 mg (31%) as a white solid. 1H-NMR (300 MHz, MeOD): 5 1.52 (6 H, s), 2.04 (1 H, s), 2.87 (3 H, s), 4.58 (2 H, s), 5.44 (2 H, s), 6.56 (1 H, s), 6.66 — 6.76 (1 H, m), 7.12 (1 H, dt), 7.25 (4 H, dtd), 7.32 — 7.44 (2 H, m).

Example 72: 2-([1-[(2-Chlorophenyl)methyl][3—(methylamino)phenyl]-1H-pyrazol yl]methoxy)—2—methylpropanoic acid.

O O /N /:N (1) Methyl 2-([1-[(2-ch10r0phenyl)methylj[3-(methylamin0)phenyl]-1H- pyrazol-S—yljmethoxy)methylpr0pan0ate: Into a 30-mL flask, paraformaldehyde (107 mg, 2.43 mmol, 5.00 equiv) was added to a solution of methyl (3-aminophenyl)—1-[(2- phenyl)methyl]—lH-pyrazolyl]methoxy]methylpropanoate (200 mg, 0.48 mmol, 1.00 equiv—-prepared analogously as described in e 69) in methanol (10 mL). This was followed by the addition of MeOna (0.45 mL, 5.00 equiv, 5.4M) se with stirring at room temperature. The resulting solution was stirred for 2 h at 60 °C in an oil bath. To this was added NaBH4 (92 mg, 2.43 mmol, 5.00 equiv) in portions at 0 °C. The resulting solution was allowed to react, with stirring, for an additional 1 h while the temperature was maintained at 60 °C in an oil bath. The resulting on was diluted with 100 mL of EtOAc.

The resulting mixture was washed with 2x50 mL of Brine. The mixture was dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto Prep-TLC with EtOAc /petroleum ether (1:4). This resulted in 100 mg (48%) of the title product as a yellow oil. (ii) 2-([1-[(2-ch10r0pheny0methylj(3-mez‘hanesulfonamidophenyl)-1H-pyrazol— 3-yljmeth0xy)methylpr0panoic acid was prepared analogously as described in Step iv of Example 1.This resulted in 30.2 mg as a white solid. 1H-NMR (300 MHz, MeOD) : 5 1.52 (6 H, s), 2.04 (1 H, s), 2.87 (3 H, s), 4.58 (2 H, s), 5.44 (2 H, s), 6.56 (1 H, s), 6.66 — 6.76 (1 H, m), 7.12 (1 H, dt), 7.25 (4 H, dtd), 7.32 — 7.44 (2 H, m).

Example 73: 2-([1-[(2-chl0r0phenyl)methyl]-5— [3-[(2-methylpropyl)amino]phenyl]-1H- pyrazol-S-yl]methoxy)methylpropanoic acid was prepared analogously as described in Example ?2.

MN / \N 1H-NMR (300 MHz, MeOD) ; 8 0.88 (6 H, d), 1.52 (6 H, s), 1.74 (1 H, dp), 2.66 (2 H, d), 4.57 (2 H, s), 5.42 (2 H, s), 6.40 — 6.77 (5 H, m), 7.11 (1 H, dd), 7.19 — 7.35 (2 H, m), 7.35 — 7.47 (1 H, m).

Example 74: 2-([1-[(0-Chlorophenyl)methyl]-5—[m-(isopr0pylamino)carb0nylphenyl]- azol-S-yl]methoxy)methylpropionic acid.

: OH 21°66;O O )N (i) 3-Acelyl-N-(pr0panyl)benzaml'de: A sion of 3-acetylbenzoic acid (10 g, 60.92 mmol), HATU (20 g, 52.60 mmol,) and propan-Z-amine (4 g, 67.6? mmol) in DMF (180 mL). To the solution pre-cooled to -5 °C was added dropwise DIEA . Then the resulting mixture was stirred at room temperature for 2 h under N2. The resulting mixture was poured into 100 mL water. The resulting residue was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with 300 mL brine, dried over anhydrous NazSO4, filtered and concentrated under vacuum. This resulted in 11 g (88%) of the title product as a yellow solid. (ii) Methyl 2-([]-[(2—ch!0r0phenyl)methylj[3-[09r0pan bamoyljphenyl]-1H-pyrazolyljmethoxy)-2—methylpr0pan0ate was prepared analogously as described in Steps i-V of Example 69. (iii) 2-([1-[(2-Ch10r0phenyl)methylj[3-[09r0panyl)carbamoyljphenylj-IH- pyrazol—3—yljmeth0xy)methylpr0pan0ic acid was prepared ously as described in Step iV of Example 1. This resulted in 80 mg as a white solid. 1H-NMR: (400 MHz, DMSO- d6) 5 1.16 (6 H, d), 1.41 (6 H, s), 3.33 (5 H, s), 4.02 — 4.17 (1 H, m), 4.44 (2 H, s), 5.40 (2 H, s), 6.53 (1 H, s), 6.75 — 6.88 (1 H, m), 7.23 — 7.36 (2 H, m), 7.41 — 7.47 (1 H, m), 7.49 — 7.57 (2 H, m), 7.81 — 7.98 (2 H, m), 8.29 (1 H, d), 12.63 (1 H, 5).

Example 75: 2-([1-[(2-chlorophenyl)methyl](phenylamino)—1H-pyrazol-3— yl]methoxy)methylpropanoic acid.

N I (i) [(2-Chlor0pheny0methyljhydrazz'ne: Into a 500-mL round-bottom flask, was placed a solution of hydrazine hydrate (85%) (31 g, 8.50 equiv) in EtOH (100 mL). This was followed by the addition of a solution of ro(chloromethyl)benzene (10 g, 62.10 mmol, 1.00 equiv) in EtOH (50 mL)(added dropwise over 1 hr at 70°C). The resulting solution was stirred for 1 h at 70 0C. The resulting mixture was concentrated under , then diluted with water. The resulting solution was extracted with EtOAc three times and the organic layers were combined. To the c phase in an ter bath was added 4N HCl in dioxane. The solids that formed were collected by filtration. This resulted in 6.1 g (63%) of the title t as a white solid. (ii) Ethyl 3-cyan0(potassicon/)prop-Z-enoate: Into a 50-mL round-bottom flask, was placed a solution of diethyl e (5.06 g, 34.62 mmol, 1.00 equiv) in CH3CN (20 mL). This was followed by the addition of t-BuOK (3.90 g, 34.76 mmol, 1.12 equiv), in portions at room temperature. The resulting solution was stirred for 1.5 h at room temperature. The solids that formed were collected by filtration. This resulted in 5.09 g (82%) of the title product as a yellow solid. (iii) Ethyl 5-amino-J—[(2-ch10r0phenyl)methylj-IH-pyrazole-3—carb0xylate: Into a 40-mL flask was placed a solution of ethyl (2Z)cyano-2—(potassiooxy)propenoate (2.0 g, 11.16 mmol, 1.00 equiv) in 1,4-dioxane (20 mL) while stirring at rt. This was followed by the addition of trifluoroacetic acid (2 mL) dropwise with stirring at room temperature. The resulting e was stirred at rt for 30 min. To this was added [(2- chlorophenyl)methyl]hydrazine (2.0 g, 12.77 mmol, 1.15 equiv), in portions at room temperature. The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 200 mL of EtOAc, washed with 2x200 mL of brine, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether (1 :3). This resulted in 1.8 g (58%) of the title product as a yellow oil. (iv) Ethyl I-[(2—chlor0pheny0methyl](pheny1amin0)-1H-pyrazoZe carboxylate: Into a 30-mL sealed tube purged and maintained with an inert atmosphere of N2, was placed a solution of ethyl 5-amino[(2-chlorophenyl)methyl]-1H-pyrazole carboxylate (1.0 g, 3.57 mmol, 1.00 equiv), iodobenzene (768 mg, 3.76 mmol, 1.05 equiv), 3rd Generation BrettPhos precatalyst (326 mg, 0.36 mmol, 0.10 equiv), and Cs2CO3 (1.4 g, 4.30 mmol, 1.20 equiv) in 1,4-dioxane (20 mL). The ing solution was stirred for 3 h at 90 0C in an oil bath. The resulting solution was diluted with 200 mL of EtOAc, washed with 2x200 mL of brine, dried over Na2S04 and concentrated under vacuum. The residue was d onto a silica gel column with PE:EtOAc:DCM (3: 1:0. 1). This resulted in 1.3 g (102%) of the title product as a yellow solid. (v) Methyl 5-[[(tert—buz‘0xy)carbonyl]09henyl)amin0][(2-chlor0phenyi)methyl]- 1H—pyrazoZecarb0xylate: Into a 50-mL round-bottom flask, was placed a solution of ethyl 1-[(2-chlorophenyl)methyl](phenylamino)-1H-pyrazolecarboxylate (800 mg, 2.25 mmol, 1.00 equiv) and thylaminopyridine (548 mg, 4.49 mmol, 2.00 equiv) in toluene (20 mL). This was ed by the addition of di-tert-butyl dicarbonate (980 mg, 4.49 mmol, 2.00 equiv), in portions at room temperature. The resulting solution was heated to reflux for 1 overnight in an oil bath. The resulting solution was d with 200 mL of EtOAc, washed with 2x100 mL of brine, dried over anhydrous Na2S04 and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1 :3). This resulted in 1.0 g (101%) of the title product as a colorless oil. (vi) 2—[(5-[[(rert—but0xy)carbonyUQahenyUam1730][(2-chlor0phenyl)methylj- 1H—pyrazoly0methoxyj—Z-mez‘hylpropanoic acid was prepared analogously as described in Steps ii-iv of Example 1. This resulted in 200 mg as yellow oil. (vii) [(2—Chlorophenybmethylfi(phenylamz‘no)-1H-pyrazolyl]meth0xy)- 2-mez‘hylpr0pan0ic acid: Into a 25-mL round-bottom flask, was placed a solution of 2-[(5- [[(tert-butoxy)carbonyl](phenyl)amino][(2-chlorophenyl)methyl]-1H—pyrazol-3 - yl)methoxy]methylpropanoic acid (200 g, 400.01 mmol, 1.00 equiv) in DCM (10 mL).

This was ed by the addition of trifluoroacetic acid (5 mL) dropwise with stirring at room temperature. The resulting solution was stirred for 1 h at room ature. The resulting e was concentrated under vacuum. The crude product (150 mg) was purified by Prep-HPLC with the following conditions alyseHPLC-SHIMADZU(HPLC-10)): Column, SunFire C18 OBD Prep Column, 0.1 nM, 5 uM, 19 mm X 150 mm, mobile phase, Waters (0.1% TFA) and ACN (61.0% ACN up to 74.0% in 6 min); or, UV 254 nm).

This resulted in 19.2 mg of the title product as a white solid. 1H-NMR (300 MHz, MeOD) 5 1.50 (6 H, s), 4.48 (2 H, s), 5.34 (2 H, d), 6.18 (1 H, s), 6.68 — 6.95 (4 H, m), 7.11 — 7.30 (4 H, m), 7.33 — 7.43 (1 H, m).

Example 76: 2-([1-[(2-Chlor0phenyl)methyl]phen0xy- lH-pyrazol-S-yl]methoxy) methylpropanoic acid.

A4OH @Odo o (i) Ethyl 1-[(2—ch10r0phenyl)methyZ]0x0-4, 5-dihydr0-1H-pyrazoZe carboxylate: Into a 250-mL round-bottom flask was placed a on of [(2— chlorophenyl)methyl]hydra.zine dihydrochloride (4 g, 17.54 mmol, 1.00 equiv) in EtOH (120 mL). 1,4-Diethyl 2—oxobutanedioate (0 mg, 1.30 equiv) was added. The resulting solution was heated to reflux overnight, then concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1 :20~1 :5). This resulted in 2.8 g (57%) of the title product as a yellow syrup. (ii) Ethyl I-[(2-ch10r0pheny0methyl]-5—(2—nitr0phen0xy)-1H—pyrazoZe carboxylate: Into a 100-mL round-bottom flask, was placed ethyl 1—[(2- chlorophenyl)methyl]oxo-4,5-dihydro-1H-pyrazole—3-carboxylate (2.8 g, 9.97 mmol, 1.00 equiv), 1-fluoronitrobenzene (2.8 g, 19.84 mmol, 2.00 equiv), K2CO3 (2.7 g, 19.57 mmol, 2.00 equiv) in DMF (20 mL). The resulting solution was stirred overnight at 90 0C in an oil bath. The resulting solution was d with EtOAc, washed with water and brine, dried over anhydrous NazSO4, and concentrated under vacuum. The residue was applied onto a silica gel WO 01426 column with EtOAc/petroleum ether 1:10). This resulted in 0.8 g (20%) of the title product as yellow oil. (iii) Ethyl 5-(2—amm0pI/zen0xy)[(2—chfor0phenyl)methylj-IH-pyrazole-S- carboxylate: Into a 50-mL round-bottom flask was placed a solution of ethyl 1-[(2- phenyl)methyl](2-nitrophenoxy)-1H-pyrazolecarboxylate (800 mg, 1.99 mmol, 1.00 equiv) in AcOH/HzO(3: 1) (8 mL). Zn (600 mg, 9.38 mmol, 5.00 equiv) was added. The resulting mixture was stirred for 3 h at 60 °C in an oil bath. The solids were removed by filtration. The resulting mixture was concentrated under vacuum. The e was applied onto a silica gel column with EtOAc/petroleum ether (1 :30~1 :5). This resulted in 540 mg (73%) of the title t as a yellow solid. (iv) Ethyl I-[(2—chlor0phenyl)methyl]-5—phen0xy—1H—pyrazolecarb0xylaz‘e: Into a 50-mL round-bottom flask was placed a solution of ethyl 5-(2-aminophenoxy)[(2- chlorophenyl)methyl]-1H-pyrazolecarboxylate (540 mg, 1.45 mmol, 1.00 equiv) in THF (15 mL). tert—Butyl nitrite (450 mg, 4.36 mmol, 3.00 equiv) was added. The solution was stirred for 30 min at 60 °C. The resulting mixture was concentrated under vacuum. The residue was purified with Prep-TLC (EtOAc:PE=1 :3) This resulted in 220 mg (42%) of the title product as a solid. (v) 2-([1-[(2-Ch10r0phenyl)methyljphen0xy-1H—pyrazolyljmeth0xy)-2— methylpropanoic acid was prepared analogously as described in Steps ii-iv of Example 1.

This resulted in 17 mg as a white solid. 1H-NMR (CD3OD, ppm): 8 (300 MHz, MeOD) 1.46 (6 H, s), 4.44 (2 H, s), 5.35 (2 H, s), 5.78 (l H, s), 6.90 — 7.00 (1 H, m), 7.06 — 7.46 (8 H, m).

Example 77: 2-([5-Benzyl[(2-chlorophenyl)methyl]-1H-pyrazolyl]methoxy) methylpropanoic acid. (i) Ethyl 2, 4-di0x0-5—phenylperztanoaz‘e: Into a 100-mL round-bottomflask was placed a solution 0f1-phenylethan0ne (1 g, 8.32 mmol, 1.00 equiv) in THF (25 mL). This was followed by the addition ofNaH (269 mg, 11.21 mmol, 1.50 , in portions at 0 0C in 30 min. To this was added diethyl oxalate (1.64 g, 11.22 mmol, 1.50 equiv). The resulting solution was stirred for 1 h at room temperature. The reaction mixture was cooled to 0 0C with a water/ice bath. The reaction was then quenched by the on of 20 mL of water. The resulting solution was extracted with 3x50 mL of EtOAc, and the c layers were combined and dried over anhydrous NazSO4 and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1:40). This resulted in 700 mg (36%) of the title product as a yellow liquid. (ii) 2-([5-Benzyl[(2-ch10r0pheny0mez‘hyl]-1H—pyrazol—3-yljmethoxy)-2—mez‘hylpr0pan0ic acid was prepared analogously as described in Steps iii-iv of Example 51. This ed in 21 mg of the product as a white solid. 1H-NMR (300 MHz, MeOD): 5 1.48 (6 H, s), 3.92 (2 H, s), 4.50 (2 H, s), 5.32 (2 H, s), 6.23 (1 H, s), 6.42 — 6.52 (1 H, m), 7.07 — 7.30 (7 H, m), 7.39 (1 H, dd).

Example 78: This example intentionally left blank.

Example 79: 2-[[1-[(2-Chlorophenyl)methyl](3—hydroxyphenyl)pyrazol yl]methoxy]methyl-pr0pan0ic acid.

HO IN\ (i) 2-[[1-[(2—ChZorophenyUmethylj(3-hydr0xypheny0pyrazol—3-yZ]meth0xy]—2— methyl-propanoic acid: A solution of methyl (3-benzyloxyphenyl)[(2-chlorophenyl)- methyl]pyrazolyl]methoxy]methyl-propanoate in mixture of acetic acid and conc HCl (8 mL) (3:1, v/v) was heated at 90 °C for 6 h. At the end of this period the reaction e was evaporated to dryness and the residue was chromatographed over Si02 using 0-20% gradient of MeOH in DCM to afford the title product. 1HNMR (CDCl3): 5 1.55 (s, 6H), 4.61 (s, 2H), 5.40(s, 2H), 6.38 (s, 1H), 6.74-6.83(m, 4H), .35(m, 4H).

Example 80: 2-[ [1- [(2-Chlor0phenyl)methyl]-5—[3-(0xetan-3—ylmeth0xy)phenyl] pyrazol- 3-yl]methoxy]methyl-propan0ic acid. $0OH R0 / \N (i) Methyl 2—[[1-[(2-ch10r0phenyl)methylj(3-hydr0xyphenyl)pyrazolyl]- methoxyj-Z-methyi—propanoaz‘e: To a solution of 2-[[l-[(2-chlorophenyl)methyl](3- hydroxyphenyl)pyrazolyl]methoxy]methyl-propanoic acid (Example 79) in MeOH was added 4 drops of cone H2804, and the solution was refluxed for 16 h. The product was evaporated to dryness and the residue was chromatographed over Si02 using 0-25% nt ofMeOH in DCM to afford the title product. (ii) Methyl [(2-chZorophenyl)methyZ][3-(oxetanylmeth0xy)phenyl]- pyrazol-3—yljmeth0xyjmethyl-propanoate. To a solution of methyl 2-[[l-[(2- chlorophenyl)methyl]-5 -(3-hydroxyphenyl)pyrazol-3 -yl]methoxy]methyl-propanoate (0.170 g, 0.410 mmol) in DMF was added ylmethyl 4-methylbenzenesulfonate (0.149 g, 0.615 mmol) and K2CO3 (0.113 g, 0.820 mol) at room temperature. The mixture was heated at 60 °C for 16 h. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with EtOAc (20 mLx2). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over NazSO4, and concentrated under reduced pressure. The residue was chromatographed over Si02 using 0- 100% gradient of EtOAc in hexane to afford the title product. 1HNMR (CDCl3): 5 1.54 (s, 6H), 3.33-3.36(m, 1H), 3.77(s, 3H), 3.97(d, 2H), 4.30 (t, 2H), , 2H), 4.84(t, 2H), 5.40(s, 2H), 6.53(s, 1H), 6.77-6.90(rn, 4H), 7.19-7.37(m, 4H). (iii) 2—[[1-[(2—Chlor0phenyl)methyZ][3-(0xetanylmethoxy)phenyl]pyrazol yljmethoxyj-Z-methyZ-propanoz‘c acid was ed analogously as described in Step iV of e 1, yielding the title product (20 mg). 1HNMR ): 5 1.55(s, 6H), 3.34-3.74 (m, 1H), 3.98 (d, 2H), 4.49 (t, 2H), 4.63(s, 2H), 4.83(t, 2H), 5.43(s, 2H), 6.44(s, 1H), 6.76- 6.93(m, 4H), 7.20-7.37(m, 4H).

Example 81: 2-[[1-[(2-chlorophenyl)methyl](3-methoxyphenyl)pyrazol yl]methoxy]methyl-N-methylsulfonyl-propanamide. o N—S\\{O I ‘,N /O N To a solution of e 14 (2-[[l-[(2-chlorophenyl)methyl](3- methoxyphenyl)pyrazolyl]methoxy]methyl-propanoic acid) (0.08 g, 0.192 mmol) in CH3CN was added CD1 (0047 g, 0.288 mmol) and methanesulfonamide (0.022g, 0.23 mmol) at rt. The mixture was stirred at rt for 16 h. The solvent was evaporated and the residue was chromatographed over Si02 using 0-20% gradient of MeOH in DCM to afford the title product. 1HNMR (CDC13): 5 155(5, 6H), 3.21(s, 3H), 3.67(s, 3H), 4.58(s, 2H), .48(s, 2H), 6.36(s, 1H), 6.75-6.92(m, 4H), 7.18-7.35(m, 4H).

Example 82: Methyl 2-[[1-[(2-chl0r0phenyl)methyl]-5—(3-methoxyphenyl)pyrazol-3— hoxy]methyl-pr0pan0ate was prepared analogously as described in Example 1, ng Step iV. 1HNMR(CDC13): 5154(5, 6H), 3.65(s, 3H), 3.77(s, 3H), 4.56(s, 2H), 5.37(s, 2H), 6.53(s, 1H), 6.71-6.78(m, 2H), 6.85-6.90(m 2H), 7.10-7.l3(m, 1H), 7.21-7.27(m,2H), 7.51-7.53(m 1H).

Biological Activity Assays The ing are assays that may be used to evaluate the biological efficacy of compounds of Formula (I) in a manner similar to that previously reported for MCTl and MCT4 and are known to those with skill in the art. See, e.g., Murray, C. M. et al., arboxylate transporter MCTl is a target for immunosuppression,” Nature chemical biology 1, 371-376 (2005); and Ovens, M. J., et al., “AR-Cl55858 is a potent inhibitor of monocarboxylate transporters MCTl and MCT2 that binds to an ellular site involving transmembrane helices 7-10,” The Biochemical Journal 425, 523-530, (2010).

Assay 1: Lactate transport in MCT4-expressing MDA-MB—453 breast cancer cells.

MCT4 may be stably expressed in MDA—MB-453 breast cancer cells that do not express native MCTl or MCT4. MCT4 activity may be ed by monitoring the intracellular pH change that anies lactate/proton symport, using the pH-sensitive fluorescent dye 2’,7’-bis-(carboxyethyl)-5(6)-carboxyfluorescein (BCECF), in a manner similar to that previously reported for MCTl and MCT4. The following is an exemplary procedure for assaying MCT4 activity of the compounds of Formula (1).

Preparing BCECF-loaded cells: Cells (~7><106) are nized (0.05% Trypsin-EDTA), pelleted (300g, 5 min), and resuspended in 1 mL Tyrode's Solution, pH 7.4 (119 mM NaCl, 5 mM KCl, 25 mM HEPES, pH 7.4, 2 mM CaClz, 2 mM MgC12, 6 g/L glucose). 10 [JL ofa 30 mM DMSO stock of AM ester (Life Technologies) is added and the cells are incubated at 37°C for 5 min. The cells are pelleted (300g, 5 min), washed once with 1 mL Tyrode’s on, pH 7.4, re-pelleted (300g, 5 min), and resuspended in 1 mL Tyrode's Solution, pH 7.4.

Lactate transport assay: 2.5 uL BCECF-loaded cells, along with either 10 [LL DMSO or 100Xcompound in DMSO, are added to 937.5 uL of Tyrode's Solution in a quartz 1.0 mL cuvette (PerkinElmer, B06311 l6). Fluorescence measurements are performed on a PerkinElmer LS55 fluorescence spectrometer with dual excitation wavelengths achieved using a filter wheel (FL Winlab program: Fast Filter, Excitation 0, on 535). After establishing baseline BCECF fluorescence (around 10-20 s), 50 [LL of 1 M sodium L-lactate (Sigma-Aldrich) is added to the cuvette (final concentration: 50 mM) and rapidly mixed. The ependent decrease in BCECF cence (490/440 ratio) may be fit to an exponential decay curve (Prism GraphPad) to determine the rate of lactate transport.

Assay 2:, MCT4-mediated lactate ort in 58 lung adenocarcinoma cells.

NCI-H358 lung adenocarcinoma cells may be used to measure MCT4 activity in cells with high native levels of MCT4 and low levels of MCT1 and are known to those with skill in the art. Preparation of BCECF-loaded cells and lactate transport activity may be determined as described for Assay 1.

Assay 3: MCT4-mediated lactate transport in MDA-MB-23l breast cancer cells. -23l breast cancer cells may be used to measure MCT4 activity in cells with high native levels of MCT4 and low levels of MCT1 and are known to those with skill in the art. Preparation of loaded cells and lactate transport activity may be determined as described for Assay 1.

Assay 4: MCT1-mediated e transport in BT20 breast cancer cells.

MCT1 activity may be measured using BT-20 breast cancer cells that express high native levels of MCT1, but do not express MCT4 and are known to those with skill in the art.

Preparation of BCECF loaded cells are as described for Assay l. Lactate transport assay is as described for Assay 1, except 10 mM L-lactate (rather than 50 mM) is added.

Results of the assays above are given below in Tables 2-3. As can be seen, most compounds disclosed herein are selective for MCT4 over MCT1.

Table 2.

MCT4 ICso (nM) MCT4 ICso (nM) MCT1 ICso (nM) MDA-MB-453 + MCT4 NCI-H358 BT20 MCT4 IC50 (nM) MCT4 IC50 (nM) MCTl ICso (nM) Example MDA-MB-453 + MCT4 NCI—H358 BT20 1 340 140 50,000 2 450 240 29,000 3 72 60 25,000 4 68 54 33,000 160 63 1,800 7 720 8 69 9 320 1 1 45 25 29,000 12 38 49 5 8,000 13 20 22 17,000 14 26 44 00 900 440 >33,000 16 1,000 640 73,000 17 440 18 5,300 19 1 10 Table 3.

MCT4 IC50 (nM) MCTI IC50 (nM) MDA-MB-231 BT20 MCT4 IC50 (nM) MCTl IC50 (nM) Example MDA-MB-231 BT20 24 30 >100,000 33 77,000 26 9.4 27,000 27 1.0 5,600 28 12 15,000 29 3.7 16,000 8.8 27,000 31 53 42,000 32 79 83,000 33 3.2 9,100 34 9.3 >11,000 5.2 59,000 36 82 50,000 37 7.6 8,400 38 48 60,000 39 5.4 10,000 40 520 >100,000 41 55 1,200 42 2.6 9,800 43 13 >33,000 44 1.1 8,400 45 19 12,000 46 142 47,000 47 410 >100,000 48 89 55,000 49 240 0 50 70 34,000 51 15 6,000 52 190 84,000 53 160 >100,000 MCT4 IC50 (nM) MCT1 IC50 (nM) Example MDA-MB-231 BT20 54 37 27,000 55 260 >100,000 56 8,000 >133,000 57 110 >133,000 58 150 78,000 59 340 81,000 60 13 44,000 61 3.1 11,000 62 33 27,000 63 37 17,000 64 8.3 45,000 65 8.0 13,000 66 7.8 45,000 67 11 17,000 68 9.1 26,000 69 5,800 >100,000 70 9,300 00 71 34,000 64,000 72 220 45,000 73 21 >11,000 74 6,400 >100,000 75 1,700 >100,000 76 400 38,000 77 340 9,000 79 59 15,000 80 81 61,000 81 6,300 6,600 82 460 16,000 Metabolic Stability Assays The following are assays that may be used to evaluate the metabolic stability of compounds of Formula (I) in human or mouse microsomes. 1. Master solution: 200 uL of 200 mM Phosphate buffer, 106 uL of ultra-pure water, 40 [LL of 50 mM MgC12, and 10 [LL of 20 mg/mL liver microsomes (human or mouse). 2. Two ted experiments were performed as follows. a) With NADPH: 10 [LL of 20 mg/mL liver microsomes and 40 [LL of 10 mM NADPH were added to the incubations. The final concentrations of omes and NADPH were 0.5 mg/mL and 1 mM, respectively. b) Without NADPH: 10 [LL of 20 mg/mL liver microsomes and 40 [LL of ultra-pure H20 were added to the incubations. The final concentration of microsomes was 0.5 mg/mL. [03 08] 3. The on was started with the addition of 4 [LL of 200 uM control compound or test compound solutions. Verapamil was used as ve control in this study. The final concentration of test compound or control compound was 2 uM. 4. Aliquots of 50 [LL were taken from the reaction solution at 0, 15, 30, 45 and 60 min. The reaction was stopped by the addition of 4 volumes of cold acetonitrile with IS (100 nM olam, 200 nM labetalol and 2 uM ketoprofen). Samples were centrifuged at 3, 220 g for 40 minutes. Aliquot of 90 uL of the supernatant was mixed with 90 uL of ultra—pure H20 and then used for LC-MS/MS analysis. 5. Data analysis. All calculations were carried out using Microsoft Excel. Peak areas were determined from extracted ion chromatograms. The slope value, k, was determined by linear regression of the l logarithm of the remaining percentage of the parent drug vs. incubation time curve. The in vitro ife (in vitro t1/2) was determined from the slope value: in vitro ti/2 = -(0.693)/k.

Results of the assays above are given below in Table 4.

Table 4 .

Human Human Mouse Mouse . . , ome microsome microsome microsome tm % 60 min % 60 min t1/2 Human Human Mouse Mouse , . , microsome microsome microsome Example microsome tm % 60 min. % 60 mm, t1/2 36 290 1200 99 39 380 u 370 88 54 78 59 760 95 57 190 80 >2000 100 64 200 270 84 65 140 560 92 66 120 260 83 68 790 380 91 Other Embodiments The detailed ption set-forth above is provided to aid those skilled in the art in practicing the t disclosure. However, the sure described and 19 herein is not to be limited in scope by the specific embodiments herein disclosed because these embodiments are intended as illustration of several aspects of the disclosure. Any equivalent embodiments are ed to be within the scope of this disclosure. Indeed, various modifications of the disclosure in on to those shown and described herein will become apparent to those skilled in the art from the foregoing description, which do not depart from the spirit or scope of the present inventive discovery. Such modifications are also intended to fall within the scope of the appended claims.

Claims (42)

CLAIMS What is claimed is:

1. A compound of structural Formula III: (III) or a salt thereof, wherein: L is chosen from a bond and methylene; wherein R4 and R5 are chosen from the following combinations: R4 and R5 are each methyl; R4 and R5 are each ethyl; and R4 is methyl and R5 is ethyl; R6 is chosen from H and methyl; Y is chosen from phenyl, thienyl, and lyl, any of which may be optionally tuted with one to three R2 groups each independently chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, haloalkyl; and Z is chosen from phenyl and pyridinyl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkyl, alkenyl, alkoxy, kyl, haloalkoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, saturated or partially saturated cycloalkyl, aryl, and aryl.

2. The compound as recited in claim 1, or a salt thereof, wherein Y is meta-substituted phenyl with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, and haloalkoxy; and Z is , substituted with one or two R3 groups chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

3. The compound as d in claim 2, or a salt thereof, wherein Y is meta-substituted with an R2 group chosen from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, isopropoxy, isobutoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclopropylmethoxy, cyclobutylmethoxy, and cyclopentylmethoxy.

4. The compound as recited in any one of claims 1-3, or a salt f, wherein Z is orthosubstituted with an R3 group chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

5. The compound as recited in claim 4, or a salt thereof, wherein Z is ortho-substituted with halo.

6. The compound as recited in claim 5, or a salt thereof, wherein Z is ortho-substituted with chloro.

7. The compound as recited in any one of claims 1-6, or a salt thereof, wherein R6 is H.

8. The compound as recited in claim 1, or a salt thereof, wherein: Y is l, substituted with an R2 group chosen from alkoxy, cycloalkoxy, lkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is phenyl, tuted with one or two R3 groups chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

9. The compound as recited in claim 8, or a salt thereof, wherein Y is substituted with an R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, and haloalkoxy.

10. The compound as recited in claim 9, or a salt thereof, wherein Y is meta-substituted with an R2 group chosen from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, isopropoxy, isobutoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclopropylmethoxy, cyclobutylmethoxy, and cyclopentylmethoxy.

11. The compound as recited in any one of claims 8-10, or a salt thereof, n Z is orthosubstituted with an R3 group chosen from , alkyl, alkylamino, halo, and haloalkyl.

12. The compound as recited in claim 11, or a salt f, wherein Z is ortho-substituted with halo.

13. The nd as recited in claim 12, or a salt thereof, wherein Z is ortho-substituted with chloro.

14. The compound as d in any one of claims 8-13, or a salt thereof, wherein R6 is H.

15. The compound as recited in claim 1, or a salt thereof, wherein: Y is thiazolyl, substituted with one R2 group chosen from alkoxy, cycloalkoxy, cycloalkylmethoxy, haloalkoxy, alkyl, halo, and haloalkyl; and Z is phenyl, substituted with one or two R3 groups chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

16. The compound as recited in claim 15, or a salt f, wherein Y is substituted with one R2 group chosen from alkoxy, cycloalkoxy, lkylmethoxy, and haloalkoxy.

17. The compound as recited in claim 16, or a salt thereof, wherein Y is meta-substituted with an R2 group chosen from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, isopropoxy, isobutoxy, cyclopropoxy, cyclobutoxy, entoxy, cyclopropylmethoxy, cyclobutylmethoxy, and cyclopentylmethoxy.

18. The nd as recited in any one of claims 15-17, or a salt thereof, wherein Z is orthosubstituted with one R3 group chosen from alkoxy, alkyl, alkylamino, halo, and haloalkyl.

19. The compound as recited in claim 18, or a salt thereof, wherein Z is ortho-substituted with one halo.

20. The compound as recited in claim 19, or a salt thereof, wherein Z is substituted with one chloro.

21. The compound as recited in any one of claims 15-20, or a salt thereof, wherein R6 is H.

22. A compound chosen from: O O Cl , , O O , Cl , , , , , , , , , , , , , Cl , , O NH , Cl , O O O OH O OH N N N N Cl Cl , , O O O OH N N Cl N N , Cl , , , , , , , O OH O OH N N , , , , O OH , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and/or a salt

23. An isolated enantiomer of a compound as recited in any one of claims 1-22.

24. A pharmaceutical composition comprising a compound as recited in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. Use of a compound as recited in claim 1, or a salt thereof, for ting activity of the monocarboxylate transporter MCT4in a ical sample ex vivo.

26. Use of a compound as recited in claim 1, or a salt thereof, in the manufacture of a medicament for inhibiting activity of the rboxylate transporter MCT4 in a t.

27. Use of a compound as recited in claim 1, or a salt thereof, in the manufacture of a medicament for selectively inhibiting activity of the monocarboxylate transporter MCT4 over activity of the monocarboxylate transporter MCT1 in a patient.

28. The use as recited in claim 27 n the inhibition is at least 100-fold selective for MCT4 over MCT1.

29. Use of a compound as recited in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a ment for treating a monocarboxylate transporter MCT4- mediated disorder in a t in need thereof.

30. The use as recited in claim 29, wherein the subject is a human.

31. The use as recited in claim 29, wherein the monocarboxylate transporter ediated disorder is chosen from an inflammatory disorder and a proliferative disorder.

32. The use as recited in claim 29, wherein the monocarboxylate transporter ediated disorder is a proliferative disorder.

33. The use as recited in claim 32, wherein the proliferative disorder is cancer.

34. The use as recited in claim 33, wherein the cancer is chosen from arcinoma, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast , brain cancer, carcinoma, myeloid a, cervical cancer, colorectal cancer, geal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular , optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central s system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, e cancer, vaginal cancer, and Wilms' tumor.

35. The use as recited in claim 29, wherein the rboxylate transporter MCT4-mediated disorder is an inflammatory disorder.

36. The use as recited in claim 35, wherein the inflammatory disorder is chosen from s disease, ulcerative colitis, idiopathic pulmonary fibrosis, muscular dystrophy, rheumatoid arthritis, and systemic sclerosis (scleroderma).

37. Use of a compound as recited in claim 1, or a ceutically acceptable salt f and a eutic agent, in the manufacture of a medicament for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof.

38. The use as recited in claim 37, wherein the therapeutic agent is a protein kinase inhibitor.

39. The use as recited in claim 38, wherein the protein kinase inhibitor is chosen from Aurora B, EGFR, PLK-1, CDKs inhibitors.

40. The use as recited in claim 37, wherein the eutic agent is chosen from an antimetabolite, bcr-abl tor, DNA damaging agent, EGFR inhibitor, microtubule izing tor, mitotic arrest inhibitor, S-phase inhibitor, and a taxane.

41. The use as recited in claim 40, wherein the therapeutic agent is a DNA damaging agent chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, DNA replication inhibitor, intercalator, microtubule disruptor, PARP tor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

42. The use as recited in claim 37, wherein the therapeutic agent is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, bcg, bicalutamide, bleomycin, lin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, icin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, ide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, lide, levamisole, lomustine, lonidamine, mechlorethamine, yprogesterone, rol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, onate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, cene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.